
CURRICULUM VITAE

CRAIG R. LEE, PHARM.D., PH.D., FCCP, FAHA

PERSONAL INFORMATION

Office Address: Campus Box 7569, 3318 Kerr Hall
Division of Pharmacotherapy and Experimental Therapeutics
UNC Eshelman School of Pharmacy
University of North Carolina at Chapel Hill
Chapel Hill, NC 27599-7569
Office: (919) 843-7673
Lab: (919) 966-9105
Email: craig_lee@unc.edu

EDUCATION AND TRAINING

Doctor of Pharmacy with Highest Distinction and Honors 1994 - 2000
School of Pharmacy
University of North Carolina at Chapel Hill

Fellowship, Clinical Research / Drug Development 2000 - 2002
Division of Pharmacotherapy
School of Pharmacy
University of North Carolina at Chapel Hill

Project: *Characterization of CYP2C9 Genotype:Phenotype Relationships in Healthy Volunteers*

Co-major advisors: John A. Pieper, Pharm.D. and J. Herbert Patterson, Pharm.D.

Clinical Development and Medical Affairs (Cardiovascular & Genitourinary)
GlaxoSmithKline, Inc.
Research Triangle Park, NC

Major advisor: Amy M. Meadowcroft, Pharm.D.

Doctor of Philosophy in Pharmaceutical Sciences 2002 - 2006
Division of Pharmacotherapy and Experimental Therapeutics
School of Pharmacy
University of North Carolina at Chapel Hill

Dissertation: *Cytochrome P450 Derived Eicosanoids, Endothelial Function and Cardiovascular Disease*

Major advisor: Darryl C. Zeldin, M.D. (NIH/NIEHS)

Committee Chair: J. Herbert Patterson, Pharm.D. (UNC)

PROFESSIONAL EXPERIENCE

Professor of Pharmacy (with Tenure) 2021 - present
Associate Professor of Pharmacy (with Tenure) 2012 - 2021
Assistant Professor of Pharmacy 2006 - 2012

Division of Pharmacotherapy and Experimental Therapeutics
UNC Eshelman School of Pharmacy

Associate Professor of Medicine (Adjunct) 2020 - present
Division of Cardiology, Department of Medicine
UNC School of Medicine

Guest Researcher 2002 - 2006
Laboratory of Respiratory Biology, Division of Intramural Research
National Institute of Environmental Health Sciences, NIH

Registered Pharmacist 2000 - present
North Carolina, License No. 15450

Leadership Positions

Vice Chair for Research and Graduate Education 2020 - present

Interim Vice Chair for Research and Graduate Education 2019 - 2020

Division Director of Graduate Studies 2016 - 2017

Division Director of Graduate Admissions 2008 - 2016
Division of Pharmacotherapy and Experimental Therapeutics
UNC Eshelman School of Pharmacy

Faculty Director, Research and Scholarship in Pharmacy (RASP) Pathway 2016 - present
UNC Eshelman School of Pharmacy

UNC Center/Program Affiliations

UNC Program for Precision Medicine in Healthcare 2019 - present

UNC Center for Pharmacogenomics and Individualized Therapy 2009 - 2019

UNC McAllister Heart Institute 2009 - present

UNC Nutrition Obesity Research Center 2007 - present

Career Development

Faculty Administrator Development Program 2015 - 2016
UNC Center for Faculty Excellence

Bill and Karen Campbell Junior Faculty Mentoring Program 2006 - 2011
UNC Eshelman School of Pharmacy

HONORS / AWARDS

Fellow, American Heart Association, Council on Clinical Cardiology (FAHA) 2015

Tenure, University of North Carolina at Chapel Hill 2012

Fellow, American College of Clinical Pharmacy (FCCP) 2011

Junior Investigator Award, ACCP Cardiology Practice and Research Network 2011

Elizabeth Barrett-Connor Research Award in Epidemiology 2005

for Young Investigators, AHA Council on Epidemiology and Prevention

Postdoctoral Award for Research Excellence, UNC-Chapel Hill 2005 - 2006

Ruth L. Kirschstein Individual National Research Service Award, NIH/NIEHS 2003 - 2006

PUBLICATIONS

(h-index: 38, [Scopus](#))

Manuscripts (*corresponding author; #equal contribution) [MyNCBI](#), [Google Scholar](#), [ORCID](#)

1. Wood B, **Lee CR**, Mulrenin IR, Gower MN, Rossi JS, Weck KE, Stouffer GA. Effects of aging on clinical outcomes in patients receiving genotype-guided P2Y12 inhibitor selection after percutaneous coronary intervention. *Pharmacotherapy*. 2021; (July 9, online ahead of print). [[PMID: 34242414](#)]
2. Morbitzer KA, McLaughlin JE, Devanathan AS, Ozawa S, McClurg MR, Carpenter DM, **Lee CR**. How-to guide for overcoming barriers of research and scholarship training in PharmD and pharmacy residency programs. *JACCP*. 2021; 4(6):743-753. [[PMID: 34355135](#)]
3. Khatri R, Fallon JK, Sykes C, Kulick N, Rementer RJB, Miner TA, Schauer AP, Kashuba ADM, Boggess KA, Brouwer KLR, Smith PC, ***Lee CR**. Pregnancy-related hormones increase UGT1A1-mediated labetalol metabolism in human hepatocytes. *Front Pharmacol*. 2021; 12: 655320. [[PMID: 33995076](#)]
4. Morbitzer KA, McLaughlin JE, Ozawa S, Beechinor R, Dumond J, Pomykal C, Bush A, Zhang Q, Carpenter D, ***Lee CR**. Implementation and initial evaluation of a research and scholarship training pathway in a PharmD curriculum. *Am J Pharm Educ*. 2021; 85(1): Article 8079, pages 55-66. [[PMID: 34281819](#)]
5. Khatri R, Kulick N, Rementer RJB, Fallon JK, Sykes C, Schauer AP, Malinen MM, Mosedale M, Watkins PB, Kashuba ADM, Boggess KA, Smith PC, Brouwer KLR, ***Lee CR**. Pregnancy related hormones increase nifedipine metabolism in human hepatocytes by inducing CYP3A4 expression. *J Pharm Sci*. 2021; 110(1):412-421. [[PMID: 32931777](#)]
6. ***Lee CR**, Thomas CD, Beitelshes AL, Tuteja S, Empey PE, Lee JC, Limdi NA, Duarte JD, Skaar TC, Chen Y, Cook KJ, Coons JC, Dillon C, Franchi F, Giri J, Gong Y, Kreutz RP, McDonough CW, Stevenson JM, Weck KE, Angiolillo DJ, Johnson JA, Stouffer GA, Cavallari LH on behalf of the IGNITE Network Pharmacogenetics Working Group. Impact of the *CYP2C19*17* allele on outcomes in patients receiving genotype-guided antiplatelet therapy after percutaneous coronary intervention. *Clin Pharmacol Ther*. 2021; 109(3):705-715. [[PMID: 32897581](#)]
7. Gustafson C, Gower MN, Williams AK, Pauley E, Weck KE, **Lee CR**, Stouffer GA. Effect of gender on clinical outcomes in patients receiving *CYP2C19* genotype-guided antiplatelet therapy after percutaneous coronary intervention. *Circ Genom Precis Med*. 2020; 13(5):554-56. [[PMID: 32938199](#)]
8. Gower MN, Ratner LR, Williams AK, Rossi JS, Stouffer GA, ***Lee CR**. Clinical utility of *CYP2C19* genotype-guided antiplatelet therapy in patients at risk of adverse cardiovascular and cerebrovascular events: a review of emerging evidence. *Pharmgenomics Pers Med*. 2020; 13:239-52. [[PMID: 32821149](#)]
9. Black RM, Williams AK, Ratner L, Crona DJ, Wiltshire T, Stouffer GA, ***Lee CR**. Projected impact of pharmacogenomic testing on medications beyond antiplatelet therapy in percutaneous coronary intervention patients. *Pharmacogenomics*. 2020; 21(7):431-41. [[PMID: 32343201](#)]
10. Theken KN, **Lee CR**, Gong L, Caudle KE, Formea CM, Gaedigk A, Klein TE, Agúndez JAG, Grosser T. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for *CYP2C9* and non-steroidal anti-inflammatory drugs. *Clin Pharmacol Ther*. 2020; 108(2):191-200. [[PMID: 32189324](#)]
11. Limdi NA, Cavallari LH, **Lee CR**, Hillegass WB, Holmes AM, Skaar TC, Pisu M, Dillon C, Beitelshes AL, Empey PE, Duarte JD, Daiby V, Gong Y, Johnson JA, Graves J, Garbett S, Zhou Z, Peterson JF on behalf of the Implementing GeNomics In pracTicE (IGNITE) Network Pharmacogenetic Working Group (IGNITE-PGx). Cost-effectiveness of *CYP2C19*-guided

antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data. *Pharmacogenomics J.* 2020; 20(5):724-35. [PMID: [32042096](#)]

12. Dong OM, Wheeler SB, Cruden G, **Lee CR**, Voora D, Dusetzina SB, Wiltshire T. Cost-effectiveness of multi-gene pharmacogenetic testing in patients with acute coronary syndrome after percutaneous coronary intervention. *Value Health.* 2020; 23(1):61-73. [PMID: [31952675](#)]
13. Martin J, Williams AK, Klein MD, Sriramoju VB, Madan S, Clarke M, Cicci JD, Rossi JS, Cavallari LH, Weck KE, Stouffer GA, ***Lee CR**. Frequency and clinical outcomes of *CYP2C19* genotype-guided escalation and de-escalation of antiplatelet therapy in a real-world clinical setting. *Genet Med.* 2020; 22(1):160-69. [PMID: [31316169](#)]
("Top 10 Advances in Genomic Medicine in 2019" by the NIH/NHGRI Genomic Medicine Working Group)
14. #Khatri R, #Fallon JK, Rementer RJB, Kulick NT, **Lee CR**, Smith PC. Targeted quantitative proteomic analysis of drug metabolizing enzymes and transporters by nano LC-MS/MS in the sandwich cultured human hepatocyte model. *J Pharmacol Toxicol Methods.* 2019; 98:106590. [PMID: [31158457](#)]
15. Williams AK, Klein MD, Martin J, Weck KE, Rossi JS, Stouffer GA, ***Lee CR**. *CYP2C19* genotype-guided antiplatelet therapy and thirty-day outcomes after percutaneous coronary intervention. *Circ Genom Precis Med.* 2019;12(2):e002441. [PMID: [30779635](#)]
16. Klein MD, Williams AK, **Lee CR**, Stouffer GA. Clinical utility of *CYP2C19* genotyping to guide antiplatelet therapy in patients with an acute coronary syndrome or undergoing percutaneous coronary intervention. *Arterioscler Thromb Vasc Biol.* 2019; 39(4):647-52. [PMID: [30760018](#)]
17. Oni-Orisan A, Cresci S, Jones PG, Theken KN, Spertus JA, ***Lee CR**. Association between the *EPHX2* p.Lys55Arg polymorphism and prognosis following an acute coronary syndrome. *Prostaglandins Other Lipid Mediat.* 2018; 138:15-22. [PMID: [30096423](#)]
18. Klein MD, **Lee CR**, Stouffer GA. Clinical outcomes of *CYP2C19* genotype-guided antiplatelet therapy: existing evidence and future directions. *Pharmacogenomics.* 2018; 19(13):1039-46. [PMID: [30028231](#)]
19. Dong OM, Li A, Suzuki O, Oni-Orisan A, Gonzalez R, Stouffer GA, **Lee CR**, Wiltshire T. Projected impact of a multi-gene pharmacogenetic test to optimize medication prescribing in cardiovascular patients. *Pharmacogenomics.* 2018; 19(9):771-82. [PMID: [29793377](#)]
20. ***Lee CR**, Sriramoju VB, Cervantes A, Howell LA, Varunok N, Madan S, Hamrick K, Polasek MJ, Lee JA, Clarke M, Cicci JD, Weck KE, Stouffer GA. Clinical outcomes and sustainability of using *CYP2C19* genotype-guided antiplatelet therapy after percutaneous coronary intervention. *Circ Genom Precis Med.* 2018; 11(4):e002069. [PMID: [29615454](#)]
([AHA News Story](#)) ([Science Magazine News Story](#)) ([MedPage Today](#)) ([CV Research Foundation News Story](#))
21. Empey PE, Stevenson J, Tuteja S, Weitzel KW, Angiolillo DJ, Beitelshes AL, Coons JC, Duarte JD, Franchi F, Jeng LJB, Johnson JA, Kreutz RP, Limdi NA, Maloney KA, Owusu Obeng A, Peterson JF, Petry N, Pratt VM, Rollini F, Scott SA, Skaar TC, Vesely MR, Stouffer GA, Wilke RA, Cavallari LH, **Lee CR** on behalf of the IGNITE Network. Multi-site investigation of strategies for the implementation of *CYP2C19* genotype-guided antiplatelet therapy. *Clin Pharmacol Ther.* 2018; 104(4): 664-674. [PMID: [29280137](#)]
22. Cavallari LH, **Lee CR**, Beitelshes AL, Cooper-DeHoff RM, Duarte JD, Voora D, Kimmel SE, McDonough CW, Gong Y, Dave CV, Pratt VM, Alestock TD, Anderson RD, Alsip J, Ardati AK, Brott BC, Brown L, Chumnumwat S, Clare-Salzler MJ, Coons JC, Denny JC, Dillon C, Elsey AR, Hamadeh I, Harada S, Hillegass WB, Hines L, Horenstein RB, Howell LA, Jeng LJB, Kelemen MD, Lee YM, Magvanjav O, Montasser M, Nelson DR, Nutescu EA, Nwaba DC, Pakyz RE, Palmer K, Peterson JF, Pollin TI, Quinn AH, Robinson SW, Schub J, Skaar TC, Smith DM, Sriramoju VB, Starostik P, Stys TP, Stevenson JM, Varunok N, Vesely MR, Wake D, Weck KE, Weitzel KW, Wilke RA, Willig J, Zhao RY, Kreutz RP, Stouffer GA, Empey PE,

- Limdi NA, Shuldiner AR, Winterstein AG, Johnson JA on behalf of the IGNITE Network. Multisite investigation of outcomes with implementation of *CYP2C19* genotype-guided antiplatelet therapy after percutaneous coronary intervention. *JACC Cardiovasc Interv.* 2018; 11(2):181-191. [PMID: 29102571] ([UNC News Story](#))
23. Seyerle AA, Sitlani CM, Noordam R, Gogarten SM, Li J, Li X, Evans DS, Sun F, Laaksonen MA, Isaacs A, Kristiansson K, Highland HM, Stewart JD, Harris TB, Trompet S, Bis JC, Peloso GM, Brody JA, Broer L, Busch EL, Duan Q, Stilp AM, O'Donnell C, MacFarlane PW, Floyd JS, Kors JA, Lin HJ, Li-Gao R, Sofer T, Mendez-Giráldez R, Cummings SR, Heckbert SR, Hofman A, Ford I, Li Y, Launer LJ, Porthan K, Newton-Cheh C, Napier MD, Kerr KF, Reiner AP, Rice KM, Roach J, Buckley BM, Soliman EZ, de Mutsert R, Sotoodehnia N, Uitterlinden AG, North KE, **Lee CR**, Gundnason V, Stürmer T, Rosendaal FR, Taylor KD, Wiggins KL, Wilson JG, Chen YD, Kaplan RC, Wilhelmsen K, Cupples LA, Salomaa V, van Duijn C, Jukema JW, Liu Y, Mook-Kanamori DO, Lange LA, Vasani RS, Smith AV, Stricker BH, Laurie CC, Rotter JI, Whitsel EA, Psaty BM, Avery CL. Pharmacogenomics study of thiazide diuretics and QT interval in multi-ethnic populations: The Cohorts for Heart and Aging Research using Genomic Epidemiology (CHARGE). *Pharmacogenomics J.* 2018; 18(2):215-226. [PMID: 28719597]
 24. Wang N, Vendrov KC, Simmons BP, Schuck RN, Stouffer GA, ***Lee CR**. Urinary 11-dehydrothromboxane B2 levels are associated with vascular inflammation and prognosis in atherosclerotic cardiovascular disease. *Prostaglandins Other Lipid Mediat.* 2018; 134:24-31. [PMID: 29155368]
 25. Ravi S, Schuck RN, Hilliard E, **Lee CR**, Dai X, Lenhart K, Willis MS, Jensen BC, Stouffer GA, Patterson C, Schisler JC. Clinical evidence supports a protective role for CXCL5 in coronary artery disease progression in the elderly. *Am J Pathol.* 2017; 187(12):2895-2911. [PMID: 29153655]
 26. Gonzalez D, Rao GG, Bailey SC, Brouwer KLR, Cao Y, Crona DJ, Kashuba ADM, **Lee CR**, Morbitzer K, Patterson JH, Wiltshire T, Easter J, Savage SW, Powell JR. Precision dosing: public health need, proposed framework, and anticipated impact. *Clin Transl Sci.* 2017; 10:443-54. [PMID: 28875519]
 27. Borse MS, Dong OM, Polasek MJ, Farley JF, Stouffer GA, ***Lee CR**. *CYP2C19*-guided antiplatelet therapy: a cost-effectiveness analysis of 30-day and 1-year outcomes following percutaneous coronary intervention. *Pharmacogenomics.* 2017; 18(12):1155-66. [PMID: 28745582]
 28. Cavallari LH, Beitelshes AL, Blake KV, Dressler LG, Duarte JD, Elsey A, Eichmeyer JN, Empey PE, Franciosi JP, Hicks JK, Holmes AM, Jeng L, **Lee CR**, Lima JJ, Limdi NA, Modlin J, Obeng AO, Petry N, Pratt VM, Skaar TC, Tuteja S, Voora D, Wagner M, Weitzel KW, Wilke RA, Peterson JF, Johnson JA. The IGNITE Pharmacogenetics Working Group: an opportunity for building evidence with pharmacogenetic implementation in a real-world setting. *Clin Transl Sci.* 2017; 10(3):143-6. [PMID: 28294551]
 29. Martin K, **Lee CR**, Farrell TM, Moll S. Oral anticoagulant use after bariatric surgery: a literature review and clinical guidance. *Am J Med.* 2017; 130(5):517-24. [PMID: 28159600]
 30. Bai X, Mangum KD, Dee RA, Stouffer GA, **Lee CR**, Oni-Orisan A, Patterson WC, Schisler JC, Viera AJ, Taylor JM, Mack CP. Blood pressure-associated polymorphism controls ARHGAP42 expression via serum response factor DNA binding. *J Clin Invest.* 2017; 127(2):670-80. [PMID: 28112683]
 31. Cavallari LH, **Lee CR**, Duarte JD, Nutescu EA, Weitzel KW, Stouffer GA, Johnson JA. Inpatient models of pharmacogenetic implementation. *Am J Health Syst Pharm.* 2016; 73(23):1944-54. [PMID: 27864202]

32. Wells MA, Vendrov KC, Edin ML, Ferslew BC, Zha W, Nguyen BKH, Church RJ, Lih FB, DeGraff LM, Brouwer KLR, Barritt AS, Zeldin DC, *Lee CR. Characterization of the cytochrome P450 epoxygenase pathway in non-alcoholic steatohepatitis. *Prostaglandins Other Lipid Mediat.* 2016; 125:19-29. [PMID: 27401401]
33. Jia J, Davis CM, Zhang W, Edin ML, Jouihan S, Jia T, Bradbury JA, Graves JP, DeGraff LM, Lee CR, Ronnekleiv O, Wang R, Xu Y, Zeldin DC, Alkayed NJ. Sex- and isoform-specific mechanism of neuroprotection by transgenic expression of P450 epoxygenase in vascular endothelium. *Exp Neurol.* 2016; 279:75-85. [PMID: 26902473]
34. Oni-Orisan A, Edin ML, Lee JA, Wells MA, Christensen ES, Vendrov KC, Lih FB, Tomer KB, Bai X, Taylor JM, Stouffer GA, Zeldin DC, *Lee CR. Cytochrome P450-derived epoxygenase products and coronary artery disease in humans: a targeted metabolomics study. *J Lipid Res.* 2016; 57(1):109-19. [PMID: 26555503]
35. Song G, Tarrant TK, White TF, Barrow DA, Santos CM, Timoschchenko RG, Hanna SK, Ramanathan RK, Lee CR, Bae-Jump VL, Gehrig PA, Zamboni WC. Roles of chemokines CCL2 and CCL5 in the pharmacokinetics of PEGylated liposomal doxorubicin in vivo and in patients with recurrent epithelial ovarian cancer. *Nanomedicine.* 2015; 11(7):1797-807. [PMID: 26093057]
36. Vanella L, Canestraro M, Lee CR, Cao J, Zeldin DC, Schwartzman ML, Abraham NG. Soluble epoxide hydrolase null mice exhibit female and male differences in regulation of vascular homeostasis. *Prostaglandins Other Lipid Mediat.* 2015; 120:139-47. [PMID: 25908301]
37. Lee JA, Lee CR, Reed BN, Plitt DC, Polasek MJ, Howell LA, Cicci JD, Tasca KE, Weck KE, Rossi JS, Stouffer GA. Implementation and evaluation of a *CYP2C19* genotype-guided antiplatelet therapy algorithm in high-risk coronary artery disease patients. *Pharmacogenomics.* 2015; 16(4):303-13. [PMID: 25823779]
38. Schuck RN, Zha W, Edin ML, Gruzdev A, Vendrov KC, Miller TM, Xu Z, Lih FB, DeGraff LM, Tomer KB, Jones HM, Makowski L, Huang L, Poloyac SM, Zeldin DC, *Lee CR. The cytochrome P450 epoxygenase pathway regulates the hepatic inflammatory response in fatty liver disease. *PLoS One.* 2014; 9(10):e110162. [PMID: 25310404]
39. Abraham NG, Sodhi K, Silvis AM, Vanella L, Favero G, Rezzani R, Lee CR, Zeldin DC, Schwartzman ML. CYP2J2 targeting to endothelial cells attenuates adiposity and vascular dysfunction in mice fed a high-fat diet by reprogramming adipocyte phenotype. *Hypertension.* 2014; 64(6):1352-61. [PMID: 25245389]
40. Zha W, Edin ML, Vendrov KC, Schuck RN, Lih FB, Jat JL, Bradbury JA, DeGraff LM, Hua K, Tomer KB, Falck JR, Zeldin DC, *Lee CR. Functional characterization of cytochrome P450-derived epoxygenase products (EETs) in adipogenesis and obesity. *J Lipid Res.* 2014; 55(10):2124-36. [PMID: 25114171]
41. Oni-Orisan A, Alsaleh N, Lee CR, Seubert JM. Epoxygenase products and cardioprotection: the road to translation. *J Mol Cell Cardiol.* 2014; 74:199-208. [PMID: 24893205]
42. Cheng J, Edin ML, Hoopes SL, Li H, Bradbury JA, Graves JP, DeGraff LM, Lih FB, Garcia V, Shaik JS, Tomer KB, Flake GP, Falck JR, Lee CR, Poloyac SM, Schwartzman ML, Zeldin DC. Vascular characterization of mice with endothelial expression of cytochrome P450 4F2. *FASEB J.* 2014; 28(7):2915-31. [PMID: 24668751]
43. Roth MT, Mumper RJ, Singleton SF, Lee CR, Rodgers PT, Cox WC, McLaughlin JE, Joyner P, Blouin RA. A renaissance in pharmacy education at the University of North Carolina at Chapel Hill. *N C Med J.* 2014; 75(1):48-52. [PMID: 24487762]

44. Panigrahy D, Kalish BT, Huang S, Bielenberg DR, Le HD, Yang J, Edin ML, **Lee CR**, Benny O, Mudge DR, Butterfield CE, Mammoto A, Mammoto T, Inceoglu B, Jenkins RL, Simpson M, Akino T, Lih FB, Tomer KB, Ingber DE, Hammock BD, Falck JR, Manthathi VL, Kaipainen A, D'Amore PA, Puder M, Zeldin DC, Kieran MW. Epoxy-eicosanoids promote organ and tissue regeneration. *Proc Natl Acad Sci U S A*. 2013; 110(33):13528-33. [PMID: 23898174]
45. #Oni-Orisan A, #Deng Y, Schuck RN, Theken KN, Edin ML, Lih FB, Molnar K, DeGraff L, Tomer KB, Zeldin DC, ***Lee CR**. Dual modulation of cyclooxygenase and CYP epoxygenase metabolism and acute vascular inflammation in mice. *Prostaglandins Other Lipid Mediat*. 2013; 104-105:67-73. [PMID: 23000418]
46. Zhang W, Davis CM, Edin ML, **Lee CR**, Zeldin DC, Alkayed NJ. Role of endothelial soluble epoxide hydrolase in cerebrovascular function and ischemic injury. *PLoS One*. 2013; 8(4):e61244. [PMID: 23585883]
47. Schuck RN, Theken KN, Edin ML, Caughey M, Bass A, Ellis K, Tran B, Steele S, Simmons BP, Lih FB, Tomer KB, Wu MC, Hinderliter AL, Stouffer GA, Zeldin DC, ***Lee CR**. Cytochrome P450-derived eicosanoids and vascular dysfunction in coronary artery disease patients. *Atherosclerosis*. 2013; 227(2):442-8. [PMID: 23466098]
48. Li R, Xu X, Chen C, Yu X, Edin ML, DeGraff LM, **Lee CR**, Zeldin DC, Wang DW. Cytochrome P450 2J2 is protective against global cerebral ischemia in transgenic mice. *Prostaglandins Other Lipid Mediat*. 2012; 99(3-4):68-78. [PMID: 23041291]
49. #Marczak ED, #Marzec J, Zeldin DC, Kleeberger SR, Brown NJ, Pretorius M, ***Lee CR**. Polymorphisms in the transcription factor NRF2 and forearm vasodilator responses in humans. *Pharmacogenet Genomics*. 2012; 22(8):620-8. [PMID: 22668754]
50. Theken KN, Schuck RN, Edin ML, Tran B, Ellis K, Bass A, Lih FB, Tomer KB, Poloyac SM, Wu MC, Hinderliter AL, Zeldin DC, Stouffer GA, ***Lee CR**. Evaluation of cytochrome P450-derived eicosanoids in humans with stable atherosclerotic cardiovascular disease. *Atherosclerosis*. 2012;222(2):530-6. [PMID: 22503544]
51. Theken KN, Deng Y, Schuck RN, Oni-Orisan A, Miller TM, Kannon MA, Poloyac SM, ***Lee CR**. Enalapril reverses high fat diet-induced alterations in cytochrome P450-mediated eicosanoid metabolism. *Am J Physiol Endocrinol Metab*. 2012;302(5):E500-9. [PMID: 22185841]
52. ***Lee CR**, Bass A, Ellis K, Tran B, Steele S, Caughey M, Stouffer GA, Hinderliter AL. Relation between digital peripheral arterial tonometry and brachial artery ultrasound measures of vascular function in patients with coronary artery disease and in healthy volunteers. *Am J Cardiol*. 2012;109(5):651-57. [PMID: 22154090]
53. #Panigrahy D, #Edin ML, #**Lee CR**, #Huang S, Bielenberg DR, Butterfield CE, Barnés CM, Mammoto A, Mammoto T, Luria A, Benny O, Chaponis DM, Dudley AC, Greene ER, Vergilio J, Pietramaggiori G, Scherer-Pietramaggiori SS, Short SM, Seth M, Lih FB, Tomer KB, Yang J, Schwendener RA, Hammock BD, Falck JR, Manthathi VM, Ingber DE, Kaipainen A, D'Amore PA, Kieran MW, Zeldin DC. Epoxy-eicosanoids stimulate multi-organ metastasis and tumor dormancy escape in mice. *J Clin Invest*. 2012;122(1):178-91. [PMID: 22182838]
54. Edin ML, Wang ZJ, Bradbury JA, Graves JP, Lih FB, DeGraff LM, Foley JF, Torphy R, Ronnekleiv OK, Tomer KB, **Lee CR**, Zeldin DC. Endothelial expression of human cytochrome P450 epoxygenase CYP2C8 increases susceptibility to ischemia-reperfusion injury in isolated mouse heart. *FASEB J*. 2011;25(10):3436-47. [PMID: 21697548]
55. Deng Y, Edin ML, Theken KN, Schuck RN, Flake GP, Kannon MA, DeGraff LM, Lih FB, Foley J, Bradbury JA, Graves JP, Tomer KB, Falck JR, Zeldin DC, ***Lee CR**. Endothelial CYP epoxygenase overexpression and soluble epoxide hydrolase disruption attenuate acute vascular inflammatory responses in mice. *FASEB J*. 2011;25(2):703-13. [PMID: 21059750]

56. ***Lee CR**, Pretorius M, Schuck RN, Burch LH, Bartlett J, Williams SM, Zeldin DC, Brown NJ. Genetic variation in soluble epoxide hydrolase (*EPHX2*) is associated with forearm vasodilator responses in humans. *Hypertension*. 2011;57(1):116-22. [[PMID: 21098312](#)]
57. Theken KN, Deng Y, Kannon MA, Miller TM, Poloyac SM, ***Lee CR**. Activation of the acute inflammatory response alters cytochrome P450 expression and eicosanoid metabolism. *Drug Metab Dispos*. 2011;39(1):22-29. [[PMID: 20947618](#)]
58. #**Lee CR**, #Imig JD, Edin ML, Foley J, DeGraff LM, Bradbury JA, Graves JP, Lih FB, Clark J, Myers P, Perrow AL, Lepp AN, Kannon MA, Ronnekleiv OK, Alkayed NJ, Falck JR, Tomer KB, Zeldin DC. Endothelial expression of human cytochrome P450 epoxygenases lowers blood pressure and attenuates hypertension-induced renal injury in mice. *FASEB J*. 2010;24(10):3770-81. [[PMID: 20495177](#)] ([The FASEB Journal Press Release](#))
59. Deng Y, Theken KN, ***Lee CR**. Cytochrome P450 epoxygenases, soluble epoxide hydrolase, and the regulation of cardiovascular inflammation. *J Mol Cell Cardiol*. 2010;48(2):331-41. [[PMID: 19891972](#)]
60. Bass A, Hinderliter AL, ***Lee CR**. The impact of ezetimibe on endothelial function and other markers of cardiovascular risk. *Ann Pharmacother*. 2009;43(12):2021-30. [[PMID: 19920161](#)]
61. Ellis K, Stouffer GA, McLeod HL, ***Lee CR**. Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations. *Pharmacogenomics*. 2009;10(11):1799-1817. [[PMID: 19891556](#)]
62. Aquilante CL, Beitelshes AL, Cavallari LH, **Lee CR**, Maciejewski S, Momary K, Vardeny O, Zineh I. Key articles relative to cardiovascular pharmacogenomics. *Pharmacotherapy*. 2009;29(9):1110-51. [[citation](#)]
63. Jackevicius CA, Page RL, Chow S, Dunn SP, **Lee CR**, Ng TMH, Rodgers JE, Vardeny O, Wiggins BS, Munger MA. High-impact articles related to the management of heart failure: 2008 update. *Pharmacotherapy*. 2009;29(1):82-112. [[PMID: 19113799](#)]
64. **Lee CR**, North KE, Bray MS, Couper DJ, Heiss G, Zeldin DC. Cyclooxygenase polymorphisms and risk of cardiovascular events: the Atherosclerosis Risk in Communities (ARIC) study. *Clin Pharmacol Ther*. 2008;83(1):52-60. [[PMID: 17495879](#)]
65. Theken KN, ***Lee CR**. Genetic variation in the cytochrome P450 epoxygenase pathway and cardiovascular disease risk. *Pharmacogenomics*. 2007;8(10):1369-1383. [[PMID: 17979511](#)]
66. Yang S, Lin L, Chen JX, **Lee CR**, Seubert JM, Wang Y, Wang H, Chao ZR, Tao DD, Gong JP, Lu ZY, Wang DW, Zeldin DC. Cytochrome P450 epoxygenases protect endothelial cells from apoptosis induced by tumor necrosis factor- α via MAPK and PI3K/Akt signaling pathways. *Am J Physiol Heart Circ Physiol*. 2007;293(1):H142-H151. [[PMID: 17322420](#)]
67. Alla F, Al-Hindi AY, **Lee CR**, Schwartz TA, Patterson JH, Adams KF. Relation of sex to morbidity and mortality in patients with heart failure and reduced or preserved left ventricular ejection fraction. *Am Heart J*. 2007;153(6):1074-80. [[PMID: 17540212](#)]
68. Dumas T, Hawke RL, ***Lee CR**. Warfarin dosing and the promise of pharmacogenomics. *Curr Clin Pharmacol*. 2007;2(1):11-21. [[PMID: 18690851](#)]
69. **Lee CR**, North KE, Bray MS, Couper DJ, Heiss G, Zeldin DC. *CYP2J2* and *CYP2C8* polymorphisms and coronary heart disease risk: the Atherosclerosis Risk in Communities (ARIC) study. *Pharmacogenet Genomics*. 2007;17(5):349-58. [[PMID: 17429317](#)]
70. **Lee CR**, Bottone FG, Krahn JM, Li L, Mohrenweiser HW, Cook ME, Petrovich RM, Bell DA, Eling TE, Zeldin DC. Identification and functional characterization of polymorphisms in human cyclooxygenase-1 (*PTGS1*). *Pharmacogenet Genomics*. 2007;17(2):145-60. [[PMID: 17301694](#)]

71. **Lee CR**, North KE, Bray MS, Avery CL, Mosher MJ, Couper DJ, Coresh J, Folsom AR, Boerwinkle E, Heiss G, Zeldin DC. *NOS3* polymorphisms, cigarette smoking, and cardiovascular disease risk: the Atherosclerosis Risk in Communities (ARIC) study. *Pharmacogenet Genomics*. 2006;16(12):891-99. [[PMID: 17108813](#)]
72. Seubert JM, Sinal CJ, Graves JP, DeGraff LM, Bradbury JA, **Lee CR**, Goralski K, Carey MA, Lauria A, Newman JW, Hammock BD, Falck JR, Roberts H, Rockman HA, Murphy E, Zeldin DC. Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function. *Circ Res*. 2006;99(4):442-50. [[PMID: 16857962](#)]
73. **Lee CR**, North KE, Bray MS, Fornage M, Seubert JM, Newman JW, Hammock BD, Couper DJ, Heiss G, Zeldin DC. Genetic variation in soluble epoxide hydrolase (*EPHX2*) and risk of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study. *Hum Mol Genet*. 2006;15(10):1640-49. [[PMID: 16595607](#)]
74. Fornage M, **Lee CR**, Doris PA, Bray MS, Heiss G, Zeldin DC, Boerwinkle E. Sequence variation in the soluble epoxide hydrolase gene is associated with ischemic stroke. *Hum Mol Genet*. 2005;14(19):2829-37. [[PMID: 16115816](#)]
75. Adams KF, Patterson JH, Gattis WA, O'Connor CM, **Lee CR**, Schwartz TA, Gheorghiadu M. Relationship of serum digoxin concentration to mortality and morbidity in women in the Digitalis Investigation Group Trial: a retrospective analysis. *J Am Coll Cardiol*. 2005;46(3):497-504. [[PMID: 16053964](#)]
76. ***Lee CR**, Hawke RL, Pieper JA. Twenty-four hour tolbutamide plasma concentrations as a phenotypic measure of CYP2C9 activity in humans. *Eur J Clin Pharmacol*. 2005;61(4):315-16. [[PMID: 15875171](#)]
77. Terra SG, Hamilton KK, Pauly DF, **Lee CR**, Patterson JH, Adams KF, Schofield RS, Belgado BS, Hill JA, Aranda JM, Yarandi HN, Johnson JA. Beta-1 adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy. *Pharmacogenet Genomics*. 2005;15(4):227-34. [[PMID: 15864115](#)]
78. Terra SG, Pauly DF, **Lee CR**, Patterson JH, Adams KF, Schofield RS, Hamilton KK, Aranda JM, Hill JA, Yarandi HN, Johnson JA. Effect of beta-adrenergic receptor polymorphisms on the tolerability of metoprolol CR/XL in patients with heart failure. *Clin Pharmacol Ther*. 2005;77(3):127-37. [[PMID: 15735607](#)]
79. Ng TMH, Carter O, Guillory GS, Howard PA, **Lee CR**, Rodgers JE, Uber PA, Wiggins BS, Munger MA, Patterson JH. High-impact articles related to the pharmacotherapeutic management of systolic heart failure. *Pharmacotherapy*. 2004;24(11):1594-1633. [[PMID: 15537564](#)]
80. ***Lee CR**. *CYP2C9* genotype as a predictor of drug disposition in humans. *Methods Find Exp Clin Pharmacol*. 2004;26(6):463-72. [[PMID: 15349140](#)]
81. **Lee CR**, Watkins ML, Patterson JH, Adams KF. Vasopressin: a new target for the treatment of heart failure. *Am Heart J*. 2003;146(1):9-18. [[PMID: 12851603](#)]
82. ***Lee CR**, Pieper JA, Hinderliter AL, Blaisdell JA, Goldstein JA. Losartan and E3174 pharmacokinetics in cytochrome P450 2C9*1/*1, *1/*2, and *1/*3 individuals. *Pharmacotherapy*. 2003;23(6):720-25. [[PMID: 12820813](#)]
83. ***Lee CR**, Pieper JA, Frye RF, Hinderliter AL, Blaisdell JA, Goldstein JA. Differences in flurbiprofen pharmacokinetics between *CYP2C9**1/*1, *1/*2, and *1/*3 genotypes. *Eur J Clin Pharmacol*. 2003;58(12):791-94. [[PMID: 12698304](#)]
84. **Lee CR**, Pieper JA, Frye RF, Hinderliter AL, Blaisdell JA, Goldstein JA. Tolbutamide, flurbiprofen and losartan as probes of CYP2C9 activity in humans. *J Clin Pharmacol*. 2003;43(1):84-91. [[PMID: 12520632](#)]

85. **Lee CR**, Pieper JA, Hinderliter AL, Blaisdell JA, Goldstein JA. Evaluation of CYP2C9 metabolic activity with tolbutamide in *CYP2C9*1* heterozygotes. *Clin Pharmacol Ther*. 2002;72(5):562-71. [[PMID: 12426520](#)]
86. **Lee CR**, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the *in vitro* and human data. *Pharmacogenetics*. 2002;12(4):251-63. [[PMID: 11927841](#)]
87. **Lee CR**, Adams KF, Patterson JH. Surrogate endpoints in heart failure. *Ann Pharmacother*. 2002;36(3):479-88. [[PMID: 11895063](#)]
88. **Lee CR**, Thrasher KA. Difficulties in anticoagulation management during co-administration of warfarin and rifampin. *Pharmacotherapy*. 2001;21(10):1240-46. [[PMID: 11601670](#)]
89. **Lee CR**, Pieper JA. Low-molecular-weight heparin therapy in acute coronary syndromes. *Hosp Pharm*. 2000;35(9):955-63. [[citation](#)]

Invited Editorials / Letters to the Editor

90. Stouffer GA, **Lee CR**. Logistical challenges associated with implementing precision medicine. *JAMA Cardiol*. 2019;4(12):1300. [[PMID: 31664434](#)]
91. Cavallari LH, **Lee CR**. A case for genotype-guided de-escalation of antiplatelet therapy after percutaneous coronary intervention. *Future Cardiol*. 2019;15(4):251-4. [[PMID: 31385522](#)]
92. ***Lee CR**, Stouffer GA. Response by Lee and Stouffer to Letter Regarding "Clinical Outcomes and Sustainability of Using *CYP2C19* Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention". *Circ Genom Precis Med*. 2018;11(7):e002258. [[PMID: 29987116](#)]
93. **Lee CR**, Zeldin DC. Clinical Implications of Basic Research: Resolvin infectious inflammation by targeting the host response. *N Engl J Med*. 2015; 373(22):2183-5. [[PMID: 26605933](#)]
94. Lee JA, ***Lee CR**. Highlights from recent advances in antiplatelet pharmacogenomics. *Per Med*. 2014; 11(2):135-8. [[PMID: 29751376](#)]
95. Simmons BP, ***Lee CR**. Research Highlights: highlights from the latest articles in personalized cardiovascular medicine. *Per Med*. 2012; 9(4):363-6. [[PMID: 29776257](#)]
96. Steele S, ***Lee CR**. Research Highlights: highlights from the latest articles in clopidogrel pharmacogenomics. *Pharmacogenomics*. 2010; 11(12):1687-90. [[citation](#)]
97. ***Lee CR**. Warfarin initiation and the potential role of genomic-guided dosing. *Clin Med Res*. 2005; 3(4):205-6. [[PMID: 16303884](#)]
98. **Lee CR**, Zeldin DC. The reality of pharmacogenomics: optimizing therapeutic decision making. *Environ Health Perspect*. 2003; 111(11):A566-7. [[PMID: 12928152](#)]

Book Chapters

1. Rodgers JE, **Lee CR**. Chapter 22: Acute Decompensated Heart Failure. In: Dipiro JT, Talbert RL, Yee GC, Matzke G, Wells B, Posey M (eds). *Pharmacotherapy: A Pathophysiologic Approach, Eighth Edition*. New York: The McGraw-Hill Companies, Inc; 2011. Pages 191-207.

Abstracts ([presenting author](#))

1. Wood BS, Mulrenin IR, Gower MN, Weck KE, Rossi JS, **Lee CR**, Stouffer GA. Examining the effects of aging on clinical outcomes in patients receiving genotype-guided P2Y12 inhibitor selection after percutaneous coronary intervention. *J Am Coll Cardiol*. 2021; 77(18 Suppl 1):1067 [abstract #15896]. Presented at the 2021 American College of Cardiology ACC.21 Conference, May 16, 2021.

2. Mulrenin IR, Gower MN, Williams AK, Weck KE, Rossi JS, Stouffer GA, **Lee CR**. Evaluation of cardiovascular outcomes in patients with diabetes following implementation of *CYP2C19* genotype-guided antiplatelet therapy in a real-world setting. *Clin Pharmacol Ther.* 2021; 108(S1):S51 [abstract #PII-025]. Presented at the 2021 American Society of Clinical Pharmacology and Therapeutics Annual Meeting, March 15, 2021. Student/Trainee Grant Award Winner.
3. Thomas CD, Empey PE, Beitelshes AL, Tuteja S, Angiolillo DJ, Limdi NA, Lee JC, Duarte JD, Skaar TC, Chen Y, Coons JC, Dillon C, Franchi F, Gong Y, Kreutz RP, McDonough CW, Stouffer GA, Johnson JA, **Lee CR**, Cavallari LH. Cardiovascular outcomes according to clinical presentation with *CYP2C19*-genotype guided antiplatelet therapy in patients undergoing PCI: a multi-site investigation in real-world settings. *Pharmacotherapy.* 2020; (in press). Presented at the 2020 American College of Clinical Pharmacy Virtual Annual Meeting. October 28, 2020.
4. Gustafson CE, Williams AK, Pauley E, Weck KE, **Lee CR**, Stouffer GA. Effect of gender on clinical outcomes in patients receiving genotype-guided antiplatelet therapy after percutaneous coronary intervention. *J Am Coll Cardiol.* 2020; 75(11 Suppl 1):1339 [abstract # 1254-047]. Presented at 2020 American College of Cardiology ACC.20/WCC Virtual Conference, March 28, 2020.
5. Gower MN, Williams AK, Gustafson C, Pauley E, Weck KE, Stouffer GA, **Lee CR**. Evaluation of cardiovascular outcomes in African-Americans following implementation of *CYP2C19* genotype-guided antiplatelet therapy in a real-world setting. *Clin Pharmacol Ther.* 2020; 107(S1):S58 [abstract # PII-084]. 2020 American Society of Clinical Pharmacology and Therapeutics Annual Meeting, March 2020. "Top Abstract" Recipient.
6. Smith S, Khatri R, Kulick N, Rementer R, Dorman KF, Boggess KA, **Lee CR**. Initial characterization of nicotinamide metabolism in pregnancy: a novel treatment for preeclampsia. *JACCP.* 2020;3(1):276 [abstract #295]. Presented at the 2019 American College of Clinical Pharmacy Annual Meeting, New York, NY. October 26, 2019.
7. Morbitzer KA, McLaughlin JE, Olsen A, Zhang Q, Dumond J, Carpenter D, Ozawa S, Smith P, Bush A, Pomykal C, **Lee CR**. Implementation and initial evaluation of an innovative approach to research and scholarship training in pharmacy education. *JACCP.* 2020;3(1):193 [abstract #108]. Presented at the 2019 American College of Clinical Pharmacy Annual Meeting, New York, NY. October 25, 2019.
8. Martin J, Williams AK, Klein MD, Sriramoju VB, Madan S, Rossi JS, Stouffer GA, **Lee CR**. *CYP2C19* genotype-guided escalation and de-escalation switching of antiplatelet therapy after percutaneous coronary intervention in a real-world setting. *Clin Pharmacol Ther.* 2019;105(S1):S23 [abstract #PT-002]. Presented at the 2019 American Society of Clinical Pharmacology and Therapeutics Annual Meeting, Washington, DC, March 13, 2019. "[Presidential Trainee Award](#)" and "Jason Morrow Trainee Award" winner.
9. Dong OM, **Lee CR**, Wheeler S, Voora D, Dusetzina S, Wiltshire T. A cost-effectiveness analysis of multi-gene pharmacogenetic testing in acute coronary syndrome patients following percutaneous coronary intervention. *Value Health.* 2018;21(S3):S6 [abstract #CV1]. Presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual European Congress. Barcelona, Spain. November 13, 2018. "Best Student Podium Research Presentation" winner.
10. Empey PE, Stevenson J, Tuteja S, Weitzel KW, Angiolillo DJ, Beitelshes AL, Coons JC, Duarte JD, Franchi F, Jeng LJB, Johnson JA, Kreutz RP, Limdi NA, Maloney KA, Obeng AO, Peterson JF, Petry N, Pratt VM, Rollini F, Scott SA, Skaar TC, Vesely MR, Stouffer GA, Wilke RA, Cavallari LH, **Lee CR**. Multi-site investigation of strategies for the implementation of *CYP2C19* genotype-guided antiplatelet therapy. *Clin Pharmacol Ther.* 2018;103(S1):S31-32

[abstract #PI-066]. Presented at the 2018 American Society of Clinical Pharmacology and Therapeutics Annual Meeting, Orlando, FL, March 22, 2018.

11. Klein M, Sriramoju VB, Cervantes A, Varunok N, Madan S, Weck KE, **Lee CR**, Stouffer GA. Thirty day clinical outcomes following implementation of *CYP2C19* genotype-guided dual antiplatelet therapy. *J Am Coll Cardiol*. 2018;71(11):1196 [abstract #1194-223]. Presented at 2018 American College of Cardiology Scientific Sessions, Orlando, FL, March 11, 2018.
12. **Lee CR**, Sriramoju VB, Cervantes A, Varunok N, Howell LA, Madan S, Weck KE, Stouffer GA. Evaluation of cardiovascular outcomes following implementation of *CYP2C19* genotype-guided antiplatelet therapy in a real-world clinical setting. *Circulation*. 2017; 136 (Suppl 1): A16575 [abstract #16575]. Presented at American Heart Association 2017 Scientific Sessions, Anaheim, CA, November 14, 2017.
13. Dong OM, Borse MS, Polasek MJ, Farley JF, Stouffer GA, **Lee CR**. *CYP2C19* guided antiplatelet therapy: a cost-effectiveness analysis of 30 day and one year outcomes following percutaneous coronary intervention. *Value Health*. 2017;20(9):A405 [abstract #CV3]. Presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual European Congress. Glasgow, Scotland. November 6, 2017.
14. Seyerle AA, Sitlani CM, North KE, **Lee CR**, Whitsel EA, Stürmer T, Avery CL. Effect of bias and exposure misclassification on gene-environment studies conducted in observational cohort settings: a simulation study. *Genet Epidemiol*. 2017; 41(7):688 [abstract #122]. Presented at 2017 Annual Meeting of the International Genetic Epidemiology Society. Cambridge, UK, September 9, 2017.
15. Dong O, Li A, Suzuki O, Oni-Orisan A, Stouffer GA, **Lee CR**, Wiltshire T. Projected impact of adopting a multiplexed preemptive genotyping intervention in cardiac catheterization laboratory patients. *Value Health*. 2017;20(5):A276 [abstract #PCV95]. Presented at International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 22nd Annual International Meeting. Boston, MA. May 23, 2017.
16. Cervantes A, Sriramoju VB, Varunok N, Hamrick K, Stouffer GA, **Lee CR**. Utilization of a *CYP2C19* genotype-guided antiplatelet treatment algorithm over time in patients undergoing percutaneous coronary intervention. *Pharmacotherapy*. 2017;37(6):e56 [abstract #76]. Presented at the 2017 American College of Clinical Pharmacy Virtual Poster Symposium. May 17, 2017. "Best Poster Award" Winner.
17. Cavallari LH, Denny JC, **Lee CR**, Beitelshes AL, Duarte JD, Kimmel SE, Voora D, McDonough CW, Gong Y, Wei W, Pratt VM, Chumnumwat S, Coons JC, Cooper-DeHoff RM, Dillon C, Hamadeh IS, Hines L, Howell LA, Jeng LJ, Lee YM, Skaar TC, Sriramoju VB, Stevenson JM, Vesely MR, Wake D, Empey PE, Kreutz RP, Stouffer GA, Wilke RA, Limdi NA, Roden DM, Shuldiner AR, Johnson JA, Peterson JF. Prospective clinical implementation of *CYP2C19*-genotype guided antiplatelet therapy after PCI: a multi-site investigation of MACE outcomes in the real world setting. *Circulation*. 2016;134(25):e711 [abstract #21050]. Presented at American Heart Association 2016 Scientific Sessions as a Late-Breaking Clinical Science Special Report: Precision Medicine on the Front Lines, New Orleans, LA, November 15, 2016. ([UNC News Story](#))
18. Sriramoju VB, Varunok N, Howell LA, Cervantes A, Polasek MJ, Stouffer GA, **Lee CR**. Risk factors for bleeding modify the impact of *CYP2C19* genetic test results on antiplatelet drug selection. *Circulation*. 2016;134(Suppl 1): A16889 [abstract #16889]. Presented at American Heart Association 2016 Scientific Sessions, New Orleans, LA, November 15, 2016.

19. Varunok N, Hamrick K, Polasek MJ, Lee JA, Wells MA, Cervantes A, Sriramoju VB, Howell L, Stouffer GA, **Lee CR**. Clinical and genetic predictors of anti-platelet therapy selection in coronary artery disease patients undergoing percutaneous coronary intervention. *Pharmacotherapy*. 2016;36(7):e113 [abstract #102]. Presented at the 2016 American College of Clinical Pharmacy Virtual Poster Symposium. May 18, 2016.
20. Schisler JC, Schuck RN, Dai X, Lenhart K, **Lee CR**, Stouffer GA, Patterson C. Clinical evidence of a protective role for CXCL5 in coronary artery disease progression in the elderly. *FASEB J*. 2016;30(S1):1117.17. Presented at Experimental Biology 2016. San Diego, CA. April 5, 2016.
21. Wells MA, Vendrov KC, Edin ML, Ferslew BC, Brouwer KLR, Barritt AS, Zeldin DC, **Lee CR**. Translational evaluation of the relationship between biomarkers of cytochrome P450-mediated eicosanoid metabolism and non-alcoholic steatohepatitis (NASH). *Clin Pharmacol Ther*. 2016;99(S1):S82 [abstract #PII-026]. Presented at the 2016 American Society of Clinical Pharmacology and Therapeutics Annual Meeting, San Diego, CA, March 11, 2016.
22. Oni-Orisan A, Edin ML, Lee JA, Stouffer GA, Zeldin DC, **Lee CR**. Characterization of the relationship between biomarkers of cytochrome P450-mediated eicosanoid metabolism and coronary artery disease severity in humans. *Clin Pharmacol Ther*. 2015;97(S1):S13 [abstract #PT-07, OIII-4]. Presented at the 2015 American Society of Clinical Pharmacology and Therapeutics Annual Meeting, New Orleans, LA, March 4, 2015. "[Presidential Trainee Award](#)" winner.
23. Oni-Orisan A, Theken KN, Schuck RN, Edin ML, Hinderliter AL, Stouffer GA, Zeldin DC, **Lee CR**. Initial characterization of cytochrome P450-derived eicosanoids as a predictive biomarker in coronary artery disease. *Pharmacotherapy*. 2014;34(10):e187 [abstract #32]. Presented at the 2014 American College of Clinical Pharmacy Annual Meeting, Austin, TX, October 13, 2014. "Best Resident and Fellow Poster Award" Winner.
24. Lee JA, Reed BN, Plitt DC, Cicci JD, Tasca K, Weck KE, **Lee CR**, Stouffer GA. Implementation and evaluation of a *CYP2C19* genotype-guided antiplatelet therapy algorithm in high-risk coronary artery disease patients. *Pharmacotherapy*. 2014;34(10):e221 [abstract #171]. Presented at the 2014 American College of Clinical Pharmacy Annual Meeting. Austin, TX, October 15, 2014. "M. Kelli Jordan Pharmacokinetics-Dynamics-Genomics Practice Research Network Travel Award" Winner.
25. Bai X, Stouffer GA, **Lee CR**, Schisler J, Patterson C, Lee JA, Oni-Orisan A, Mack CP, Taylor, JM. The smooth muscle-selective RhoGAP Graf3 is a critical regulator of vascular tone and hypertension. *Hypertension*. 2014;64(Suppl1):A627 [abstract 627]. Presented at the American Heart Association High Blood Pressure Research 2014 Scientific Sessions, San Francisco, CA, September, 2014.
26. Reed BR, Wittorf R, Plitt DC, Weck KE, **Lee CR**, Stouffer GA. Influence of clinical and genetic characteristics on P2Y12 inhibitor selection in high-risk patients with coronary artery disease. *Pharmacotherapy*. 2013;33(10):e191 [abstract 30]. Presented at the 2013 American College of Clinical Pharmacy Annual Meeting, Albuquerque, NM, October, 2013.
27. Simmons BP, Schuck RN, Molnar K, Steele S, Caughey M, Hinderliter AL, Stouffer GA, **Lee CR**. Thromboxane and prostaglandin metabolite levels and inflammation phenotypes in coronary artery disease patients. *Pharmacotherapy*. 2012;32(10):e189 [abstract 39]. Presented at the 2012 American College of Clinical Pharmacy Annual Meeting, Hollywood, FL, October 22, 2012. "Best Resident and Fellow Poster Award" Finalist.

28. Steele S, Tran B, Ellis K, Bass A, Schuck RN, Caughey M, Stouffer GA, Hinderliter AL, **Lee CR**. Endothelial nitric oxide synthase polymorphisms and endothelial function in coronary artery disease patients. *Pharmacotherapy*. 2011;31(10):e371-2 [abstract 220]. Presented at the Great Eight Session, 2011 American College of Clinical Pharmacy Annual Meeting, Pittsburgh, PA, October 16, 2011. "Best Poster Award" Finalist.
29. Schuck RN, Theken KN, Edin ML, Caughey M, Tran B, Steele S, Ellis K, Bass A, Lih FB, Tomer KB, Zeldin DC, Stouffer GA, Hinderliter AL, **Lee CR**. Inverse correlation between plasma 20-Hydroxyeicosatetraenoic acid levels and endothelial function in patients with hypertension and coronary artery disease. *Arterioscler Thromb Vasc Biol*. 2011; [abstract P388]. Presented at Arteriosclerosis, Thrombosis, and Vascular Biology 2011 Scientific Sessions, Chicago, IL, April 2011.
30. Theken KN, Deng Y, Schuck RN, Kannon MA, Miller TM, Poloyac SM, **Lee CR**. High-fat diet suppresses hepatic cytochrome P450-mediated eicosanoid metabolism in mice. *AAPS J*. 2010; 12(S2) [abstract W4325]. Presented at the International Pharmaceutical Federation Pharmaceutical Sciences World Congress/American Association of Pharmaceutical Scientists Annual Meeting, New Orleans, LA, November 2010.
31. Theken KN, Deng Y, Kannon MA, Miller TM, Poloyac SM, **Lee CR**. Lipopolysaccharide suppresses hepatic and extra-hepatic cytochrome P450 expression and arachidonic acid-metabolizing activity in mice. *AAPS J*. 2010; 12(S2) [abstract W4326]. Presented at the International Pharmaceutical Federation Pharmaceutical Sciences World Congress/American Association of Pharmaceutical Scientists Annual Meeting, New Orleans, LA, November 2010.
32. Tran B, Ellis K, Bass A, Caughey M, Theken KN, Schuck RN, Stouffer GA, Hinderliter AL, **Lee CR**. Evaluation of peripheral arterial tonometry in coronary artery disease patients and healthy volunteers. *Pharmacotherapy*. 2010;30(10):444e [abstract 280]. Presented at the 2010 American College of Clinical Pharmacy Annual Meeting, Austin, TX, October 2010.
33. **Lee CR**, Pretorius M, Schuck RN, Burch LH, Williams SM, Zeldin DC, Brown NJ. Genetic variation in soluble epoxide hydrolase is associated with vascular responsiveness to bradykinin in humans. *Hypertension*. 2010;56(5):e148 [abstract P447]. Presented at the American Heart Association High Blood Pressure Research 2010 Scientific Sessions, Washington, DC, October 15, 2010.
34. **Lee CR**, Tran B, Ellis K, Bass A, Caughey M, Stouffer GA, Hinderliter AL. Relationships between digital peripheral arterial tonometry and brachial artery velocity measures of endothelial function in humans. *Hypertension*. 2010;56(5):e150 [abstract P457]. Presented at the American Heart Association High Blood Pressure Research 2010 Scientific Sessions, Washington, DC, October 15, 2010.
35. Ellis K, Bass A, Tran B, Caughey M, Stouffer GA, Hinderliter AL, **Lee CR**. Evaluation of endothelial function using peripheral arterial tonometry in coronary artery disease patients treated for depression. *Pharmacotherapy*. 2010;30(4):180e [abstract 107]. Presented at the 2010 American College of Clinical Pharmacy Spring Practice and Research Forum, Charlotte, NC, April 26, 2010.
36. Ellis K, Bass A, Theken KN, Caughey M, Burch LH, Brown NJ, Zeldin DC, Stouffer GA, Hinderliter AL, **Lee CR**. Cyclooxygenase-2 and endothelial nitric oxide synthase polymorphisms and endothelial function in coronary artery disease patients. *Pharmacotherapy*. 2009;29(10):232e [abstract 176]. Presented at the 2009 American College of Clinical Pharmacy Annual Meeting, Anaheim, CA, October 21, 2009.

37. Deng Y, Theken KN, Edin ML, Kannon MA, Schuck RN, DeGraff L, Bradbury JA, Graves J, Zeldin DC, **Lee CR**. Endothelial CYP2J2 and CYP2C8 over-expression and soluble epoxide hydrolase deletion attenuate acute inflammatory responses in mice. *Arterioscler Thromb Vasc Biol.* 2009;29(7):e63 [abstract P286]. Presented at Arteriosclerosis, Thrombosis, and Vascular Biology 2009 Scientific Sessions. Washington D.C., April 30, 2009.
38. **Lee CR**, Bass A, Ellis K, Caughey M, Stouffer GA, Hinderliter AL. Relationships between peripheral arterial tonometry and brachial artery ultrasound measures of endothelial function in patients with established atherosclerosis. *Arterioscler Thromb Vasc Biol.* 2009;29(7):e55-56 [abstract P244]. Presented at Arteriosclerosis, Thrombosis, and Vascular Biology 2009 Scientific Sessions. Washington D.C., April 29, 2009.
39. Jia J, **Lee CR**, DeGraff LM, Bradbury JA, Zeldin DC, Alkayed NJ. P450 epoxygenase overexpression in vascular endothelium alters blood flow and infarct size after middle cerebral artery occlusion in a sex- and isoform-specific manner. *Stroke.* 2009;40(4):45 [abstract 187]. Presented at the International Stroke Conference 2009, San Diego, CA, February 20, 2009.
40. Bass A, Caughey M, Hull JH, Stouffer GA, Hinderliter AL, **Lee CR**. Phenotypic characterization of endothelial function in individuals with established atherosclerosis using two non-invasive methods. *Pharmacotherapy.* 2008;28(10):120 [abstract 19]. Presented at the 2008 American College of Clinical Pharmacy Annual Meeting, Louisville, KY, October 21, 2008. "Best Resident and Fellow Poster Award" Finalist.
41. Imig JD, **Lee CR**, Bradbury JA, Graves JP, DeGraff LM, Foley J, Zeldin DC. CYP2J2 endothelial overexpression increases nitric oxide and cyclooxygenase independent renal dilation and attenuates endothelin-1 vasoconstriction. *Circulation.* 2007;116:II-295-296 [abstract 1436]. Presented at the American Heart Association Scientific Sessions 2007, Orlando, FL, November 7, 2007.
42. **Lee CR**, North KE, Bray MS, Couper DJ, Heiss G, Zeldin DC. Genetic variation in *CYP2J2* and risk of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. *Circulation.* 2006;114(18):II-490 [abstract 2386]. Presented at the American Heart Association Scientific Sessions 2006, Chicago, IL, November 13, 2006.
43. **Lee CR**, North KE, Bray MS, Couper DJ, Heiss G, Zeldin DC. The G-765C promoter polymorphism in cyclooxygenase-2 (*PTGS2*), aspirin utilization and cardiovascular disease risk: the Atherosclerosis Risk in Communities (ARIC) Study. *Pharmacotherapy.* 2006;26(suppl):e87 [abstract 227]. Presented at the 2006 American College of Clinical Pharmacy Annual Meeting, St. Louis, MO, October 27, 2006.
44. Alla FM, Al-Hindi AY, **Lee CR**, Schwartz TA, Patterson JH, Ghali JK, Adams KF. Diabetes reduces the likelihood of more favorable outcomes in women than men with heart failure: a retrospective analysis from the Digitalis Investigation Group (DIG) Trial. *J Card Failure.* 2006;12(6):S94 [abstract 303]. Presented at the 10th Heart Failure Society of America Annual Scientific Meeting, Seattle, WA, September 2006.
45. Adams KF, Patterson JH, Stough WG, Alla FM, O'Connor CM, **Lee CR**, Schwartz TA, Gheorghide M. Relationship of clinical signs and chest X-ray congestion to the efficacy of digoxin in patients with chronic heart failure: a retrospective analysis from the Digitalis Investigation Group (DIG) Trial. *J Card Failure.* 2006;12(6):S87-88 [abstract 282]. Presented at the 10th Heart Failure Society of America Annual Scientific Meeting, Seattle, WA, September 2006.

46. **Lee CR**, North KE, Bray MS, Fornage M, Seubert JM, Couper DJ, Heiss G, Zeldin DC. Genetic variation in soluble epoxide hydrolase (*EPHX2*) and risk of coronary heart disease: an Atherosclerosis Risk in Communities (ARIC) study. *Circulation*. 2005;112(17):II-821 [abstract 3801]. Presented at the American Heart Association Scientific Sessions 2005, Dallas, TX, November 15, 2005. "Elizabeth Barrett-Connor Research Award in Epidemiology for Young Investigators" winner.
47. **Alla FM**, Al-Hindi AY, **Lee CR**, Schwartz TA, Patterson JH, Adams KF. Women have reduced risk for hospitalization in heart failure due to left ventricular dysfunction but not preserved ejection fraction: retrospective analysis of the Digitalis Investigation Group (DIG) Trial. *Circulation*. 2005;112(17):II-410 [abstract 1996]. Presented at the American Heart Association Scientific Sessions 2005, Dallas, TX, November 14, 2005.
48. **Lee CR**, North KE, Bray MS, Avery CL, Mosher MJ, Couper DJ, Heiss G, Zeldin DC. Genetic variation in endothelial nitric oxide synthase (*NOS3*) and risk of coronary heart disease: an Atherosclerosis Risk in Communities (ARIC) study. *Pharmacotherapy*. 2005;25(10):1479 [abstract 292]. Presented at the 2005 American College of Clinical Pharmacy Annual Meeting, San Francisco, CA, October 24, 2005.
49. **Lee CR**, North KE, Bray MS, Couper DJ, Heiss G, Zeldin DC. Genetic variation in cyclooxygenase-1 (*PTGS1*) and risk of ischemic stroke: an Atherosclerosis Risk in Communities (ARIC) study. *Pharmacotherapy*. 2005;25(10):1479 [abstract 293]. Presented at the 2005 American College of Clinical Pharmacy Annual Meeting, San Francisco, CA, October 24, 2005. "Best Poster Award" Finalist.
50. **Al-Hindi AY**, **Lee CR**, Schwartz TA, Patterson JH, Alla FM, Adams KF. Chest X-ray predicts outcome in heart failure patients with preserved and reduced ejection fraction: analysis from the Digitalis Investigation Group (DIG) Trial. *J Card Failure*. 2005;11(6):S170. Presented at the 9th Heart Failure Society of America Annual Scientific Meeting, Boca Raton, FL, September 19, 2005.
51. **Al-Hindi AY**, **Lee CR**, Patterson JH, Schwartz TA, Alla FM, Adams KF. Signs but not symptoms predict outcome in heart failure with preserved and reduced ejection fraction: analysis from the Digitalis Investigation Group (DIG) Trial. *J Card Failure*. 2005;11(6):S173. Presented at the 9th Heart Failure Society of America Annual Scientific Meeting, Boca Raton, FL, September 19, 2005.
52. **North KE**, Mosher MJ, Avery CL, Coresh J, Boerwinkle E, Zeldin DC, **Lee CR**, Couper D, Bray MS. Endothelial nitric oxide synthase (*eNOS*) Glu298Asp polymorphism association with coronary heart disease risk is modified by smoking: the Atherosclerosis Risk in Communities Study. *Circulation*. 2004;110(17):III-823 [abstract 3800]. Presented at the American Heart Association Scientific Sessions 2004, New Orleans, LA, November, 2004.
53. **Lee CR**, Pieper JA, Hawke RL, Hinderliter AL, Blaisdell JA, Goldstein JA. Twenty-four hour tolbutamide plasma concentrations as a phenotypic measure of CYP2C9 activity in humans. *Pharmacotherapy*. 2004;24(10):1469 [abstract 261]. Presented at the 2004 American College of Clinical Pharmacy Annual Meeting, Dallas, TX, October 25, 2004.
54. **Alla FM**, Patterson JH, Gattis WA, O'Connor CM, **Lee CR**, Schwartz TA, Gheorghide M, Adams KF. Women with preserved systolic function have better survival than men: retrospective analysis of the Digitalis Investigational Group (DIG) Trial. *J Card Failure*. 2004;10(4):S90. Presented at the 8th Heart Failure Society of America Annual Scientific Meeting, Toronto, Canada, September 14, 2004.
55. Adams KF, Patterson JH, Gattis WA, O'Connor CM, **Lee CR**, Schwartz TA, Gheorghide M. Relationship of serum digoxin concentration to mortality and morbidity in women in the Digitalis Investigation Group (DIG) Trial: A Retrospective Analysis. *J Card Failure*.

- 2004;10(4):S23. Presented at the 8th Heart Failure Society of America Annual Scientific Meeting, Toronto, Canada, September 13, 2004.
56. **Lee CR**, Patterson JH, Gattis WA, O'Connor CM, Schwartz TA, Gheorghiade M, Adams KF. Renal function, independent of ejection fraction and heart size, is a predictor of mortality in patients with heart failure and preserved ejection fraction: a retrospective analysis of the Digitalis Investigational Group (DIG) Trial. *J Card Failure*. 2004;10(4):S87. Presented at the 8th Heart Failure Society of America Annual Scientific Meeting, Toronto, Canada, September 13, 2004.
 57. Patterson JH, **Lee CR**, Gheorghiade M, Gattis WA, O'Connor CM, Schwartz TA, Adams KF. Clinical severity predicts response to digoxin: a retrospective analysis of the Digitalis Investigational Group (DIG) Trial. *J Card Failure*. 2004;10(4):S87. Presented at the 8th Heart Failure Society of America Annual Scientific Meeting, Toronto, Canada, September 2004.
 58. **Terra SG**, Hamilton KK, Pauly DF, **Lee CR**, Patterson JH, Adams KF, Schofield RS, Hill JA, Aranda JM, Yarandi HN, Johnson JA. Arg389Gly beta-1 adrenergic receptor polymorphism and left ventricular remodeling changes to beta-blocker therapy. *Clin Pharmacol Ther*. 2004;75(2):P2 [abstract OI-A-4]. Presented at the 105th American Society of Clinical Pharmacology and Therapeutics Annual Meeting, Miami, FL, March 2004.
 59. **Terra SG**, Pauly DF, **Lee CR**, Patterson JH, Adams KF, Schofield RS, Hamilton KK, Hill JA, Aranda JM, Johnson JA. Effect of beta-1 adrenergic receptor polymorphisms on the tolerability of metoprolol CR/XL in heart failure. *Clin Pharmacol Ther*. 2004;75(2):P16 [abstract PI-49]. Presented at the 105th American Society of Clinical Pharmacology and Therapeutics Annual Meeting, Miami, FL, March 2004.
 60. **Lee CR**, Patterson JH, Gattis WA, Ghali J, Shah PJ, Schwartz TA, Gheorghiade M, Adams KF. Renal dysfunction is common in patients with heart failure and preserved systolic function: retrospective analysis of the Digitalis Investigational Group (DIG) trial. *Circulation*. 2003;108(17):IV-484-5 [abstract 2220]. Presented at the American Heart Association Scientific Sessions 2003, Orlando, FL, November 10, 2003.
 61. **Lee CR**, Shah PJ, Adams KF, Gattis WA, O'Connor CM, Gheorghiade M, Schwartz TA, Patterson JH. Variability in serum digoxin concentrations (SDCs) in the Digitalis Investigational Group (DIG) trial: a retrospective analysis. *Pharmacotherapy*. 2003;23(10):1331 [abstract 22]. Presented at the 2003 American College of Clinical Pharmacy Annual Meeting, Atlanta, GA, November 5, 2003.
 62. **Shah PJ**, Patterson JH, Gattis WA, Ghali J, **Lee CR**, O'Connor CM, Schwartz TA, Gheorghiade M, Adams KF. Risk of death in patients with preserved systolic function: retrospective analysis of the Digitalis Investigational Group (DIG) trial. *J Card Failure*. 2003;9(5 Suppl 1):S85 [abstract 313]. Presented at the 7th Heart Failure Society of America Annual Scientific Meeting, Las Vegas, NV, September 2003.
 63. **Lee CR**, Pieper JA, Frye RF, Hinderliter AL, Blaisdell JA, Goldstein JA. Assessment of CYP2C9 phenotypic:genotypic relationships with potential probes. *Clin Pharmacol Ther*. 2002;71(2):25 [abstract MPI-81]. Presented at the 103rd American Society of Clinical Pharmacology and Therapeutics Annual Meeting, Atlanta, GA, March 25, 2002. "Top Abstract" Recipient.
 64. **Lee CR**, Pieper JA, Hinderliter AL, Blaisdell JA, Goldstein JA. Alterations in tolbutamide disposition in CYP2C9*1 heterozygotes. *Clin Pharmacol Ther*. 2002;71(2):30 [abstract MPI-98]. Presented at the 103rd American Society of Clinical Pharmacology and Therapeutics Annual Meeting, Atlanta, GA, March 25, 2002.

65. **Lee CR**, Pieper JA, Frye RF, Hinderliter AL, Blaisdell JA, Goldstein JA. Consequences of CYP2C9 polymorphisms on flurbiprofen pharmacokinetics. Clin Pharmacol Ther. 2002;71(2):62 [abstract TPII-77]. Presented at the 103rd American Society of Clinical Pharmacology and Therapeutics Annual Meeting, Atlanta, GA, March 26, 2002.
66. Pieper JA, **Lee CR**, Hinderliter AL, Clarke MJ, Blaisdell JA, Goldstein JA. Effect of CYP2C9 genotype on losartan disposition. Clin Pharmacol Ther. 2002;71(2):68 [abstract TPII-98]. Presented at the 103rd American Society of Clinical Pharmacology and Therapeutics Annual Meeting, Atlanta, GA, March 26, 2002.
67. **Lee CR**, Pieper JA, Goldstein JA, Blaisdell J, Clarke MJ, Hinderliter AL. Pharmacokinetic and pharmacodynamic consequences of CYP2C9 genetic polymorphisms with losartan. Pharmacotherapy. 2001;21(10):1286 [abstract 204]. Presented at the 2001 American College of Clinical Pharmacy Annual Meeting, Tampa Bay, FL, October 22, 2001.

Meeting Proceedings (presenting author)

68. **Black RM**, Williams AK, Stouffer GA, **Lee CR**. Projected impact of CYP2C19 pharmacogenomic testing on optimizing medications in addition to antiplatelet therapy in a real-world setting [abstract #5-296]. 54th American Society of Health-System Pharmacists Midyear Clinical Meeting. Las Vegas, NV. December 9, 2019.
69. **Varma Y**, **Lee CR**, Rossi J, Stouffer GA. Association of CYP2C19*17 allele and choice of P2Y12 inhibitor on cardiovascular outcomes following percutaneous coronary intervention [abstract #III-86]. Presented at the 2019 Society for Cardiovascular Angiography and Interventions Scientific Sessions. Las Vegas, NV, May 21, 2019.
70. **Robbins MJ**, Rementer RJ, Williams A, Oni-Orisan A, **Lee CR**. Association between novel circulating biomarkers of cytochrome P450-derived eicosanoid metabolism and prognosis in patients with established atherosclerotic cardiovascular disease [abstract #556061]. 53rd American Society of Health-System Pharmacists Midyear Clinical Meeting. Anaheim, CA. December 4, 2018.
71. **Khatri R**, Bacheler R, Malinen M, Fallon JK, Sykes C, Smith PC, Kashuba ADM, Brouwer KLR, **Lee CR**. Pregnancy-related hormones increase nifedipine metabolism in sandwich-cultured human hepatocytes by inducing CYP3A expression. 48th Drug Metabolism Gordon Research Conference. Holderness, NH, July 9, 2018.
72. **Limdi NA**, Holmes A, Skaar T, Cavallari L, Beitelshees AL, Dillon C, Duarte J, Empey PE, Gong Y, Hillegass WB, Johnson JA, **Lee CR**, Graves J, Garbett S, Zhou Z, Peterson JF. Real world cost-effectiveness of CYP2C19 guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention [abstract #PS3-14]. 39th Annual Meeting of the Society for Medical Decision Making (SMDM). Pittsburgh, PA. October 24, 2017.
73. **Cervantes A**, Sriramoju VB, Varunok N, Stouffer GA, **Lee CR**. Utilization of a CYP2C19 genotype-guided antiplatelet treatment algorithm over time in patients undergoing percutaneous coronary intervention [abstract #237805]. 51st American Society of Health-System Pharmacists Midyear Clinical Meeting. Las Vegas, NV. December 6, 2016.
74. **Wang N**, Vendrov K, Simmons BP, **Lee CR**. Evaluation of thromboxane A2 as a biomarker for predicting adverse cardiovascular outcomes in patients with stable coronary artery disease [abstract #235223]. 51st American Society of Health-System Pharmacists Midyear Clinical Meeting. Las Vegas, NV. December 5, 2016.

75. Li A, Dong O, Oni-Orisan A, Wiltshire T, **Lee CR**. Projected impact of genotype-guided optimization of medication use: an opportunity for preemptive genotyping in cardiac catheterization laboratory patients [abstract #240451]. 51st American Society of Health-System Pharmacists Midyear Clinical Meeting. Las Vegas, NV. December 5, 2016.
76. Hamrick K, Polasek M, Stouffer GA, **Lee CR**. Predictors of *CYP2C19* genotype testing and anti-platelet therapy selection patients undergoing percutaneous coronary intervention [abstract #5B-306]. 50th American Society of Health-System Pharmacists Midyear Clinical Meeting. New Orleans, LA. December, 2015.
77. Varunok N, Danford RC, Polasek M, Howell L, **Lee CR**, Stouffer GA. Exploring the effects of genotype-guided P2Y12 inhibitor therapy on major adverse cardiovascular and clinically significant bleeding events in practice. 161st North Carolina Medical Society Annual Meeting. Greensboro, NC. October 23, 2015.
78. Christensen ES, Oni-Orisan A, Lee JA, Stouffer GA, **Lee CR**. *Predictors of coronary artery disease progression and poor cardiovascular outcomes in patients referred for coronary angiography* [abstract #2-259]. 49th American Society of Health-System Pharmacists Midyear Clinical Meeting. Orange County, CA. December 8, 2014.
79. Danford RC, Polasek M, Lee JA, Stouffer GA, **Lee CR**. *Retrospective analysis of clinical and CYP2C19 genetic predictors of anti-platelet therapy selection in patients undergoing percutaneous coronary intervention* [abstract #2-262]. 49th American Society of Health-System Pharmacists Midyear Clinical Meeting. Orange County, CA. December 8, 2014.
80. Puglisi J, **Lee CR**, Crane P. *Practice and outcomes in older adult coronary patients with low vitamin D*. 33rd Annual Gerontological Advanced Practice Nurses Association Conference. Orlando, FL. September, 2014.
81. Cheng J, Edin ML, DeGraff LM, **Lee CR**, Falck JR, Zeldin DC. *In vitro cell proliferation, angiogenesis and oxidative stress are elevated in mice with endothelial-specific expression of human CYP4F2*. 14th Annual Winter Eicosanoid Conference. Baltimore, MD, March 12, 2012.
82. Oni-Orisan A, Deng Y, Schuck RN, Edin ML, Theken KN, Molnar K, DeGraff L, Zeldin DC, **Lee CR**. *Cyclooxygenase inhibition, CYP2J2 overexpression, and soluble epoxide hydrolase deletion similarly attenuate lipopolysaccharide-induced acute vascular inflammation*. 14th Annual Winter Eicosanoid Conference. Baltimore, MD, March 12, 2012. "Travel Award" recipient.
83. Kalish BT, Kieran MW, Le HD, Bielenberg DR, **Lee CR**, Edin ML, Greene ER, Vergilio JA, Hammock BD, Falck JR, Puder M, Zeldin DC, Panigrahy D. *Epoxyeicosatrienoic acids promote organ regeneration*. 14th Annual Winter Eicosanoid Conference. Baltimore, MD, March 11, 2012.
84. Schuck RN, Theken KN, Edin ML, Lih FB, Tomer KB, Caughey M, Hinderliter AL, Stouffer GA, Zeldin DC, **Lee CR**. *Association between cytochrome P450 derived eicosanoids and vascular function in humans with established coronary artery disease*. 14th Annual Winter Eicosanoid Conference. Baltimore, MD, March 11, 2012. "Travel Award" recipient.
85. **Lee CR**, Gordon LN, Pretorius M, Schuck RN, Burch LH, Zeldin DC, Williams S, Brown NJ. *Interactions between polymorphisms in eicosanoid metabolism genes and vasodilator responses in humans*. 14th Annual Winter Eicosanoid Conference. Baltimore, MD, March 11, 2012.
86. Theken KN, Deng Y, Schuck RN, Kannon MA, Miller TM, Poloyac SM, **Lee CR**. *High-fat diet alters hepatic and renal cytochrome P450-mediated eicosanoid metabolism in mice*. 2010; [abstract PD-W-15]. 2010 Globalization of Pharmaceuticals Education Network Conference. Chapel Hill, NC, November 10, 2010.

87. Edin ML, Wang Z, Bradbury JA, Graves JP, Lih FB, DeGraff LM, **Lee CR**, Zeldin DC. *Endothelial-specific overexpression of human CYP2C8 increases susceptibility to ischemia-reperfusion injury in isolated mouse heart*. 12th Annual Winter Eicosanoid Conference. Baltimore, MD, March 8, 2010.
88. **Lee CR**, Pretorius M, Williams SM, Burch LH, Zeldin DC, Brown NJ. *Genetic variation in soluble epoxide hydrolase is associated with vascular responsiveness to bradykinin in humans*. 12th Annual Winter Eicosanoid Conference. Baltimore, MD, March 8, 2010.
89. Theken KN, Deng Y, Schuck RN, Kannon MA, Miller TM, Poloyac SM, **Lee CR**. *High-fat diet suppresses hepatic cytochrome P450 expression and metabolic activity in mice*. 12th Annual Winter Eicosanoid Conference. Baltimore, MD, March 8, 2010. "Travel Award" recipient.
90. **Lee CR**, Imig JD, Edin ML, Foley J, DeGraff LM, Bradbury JA, Graves JP, Lih FB, Tomer KB, Zeldin DC. *Endothelial expression of human cytochrome P450 epoxygenases lowers blood pressure and attenuates hypertension-induced renal injury in mice*. 12th Annual Winter Eicosanoid Conference. Baltimore, MD, March 8, 2010. "Travel Award" recipient.
91. Theken KN, Deng Y, Kannon MA, **Lee CR**. *Effects of Acute Inflammation on Cardiovascular Cytochrome P450 and soluble epoxide hydrolase expression in mice in vivo*. 11th Annual Winter Eicosanoid Conference. Baltimore, MD, March 10, 2009.
92. Deng Y, Theken KN, Edin ML, Kannon MA, Schuck RN, DeGraff L, Bradbury JA, Graves J, Zeldin DC, **Lee CR**. *Endothelial CYP2J2 and CYP2C8 overexpression and soluble epoxide hydrolase deletion attenuate acute inflammatory responses in mice*. 11th Annual Winter Eicosanoid Conference. Baltimore, MD, March 8, 2009.
93. Deng Y, Theken KN, Edin ML, Kannon MA, DeGraff L, Bradbury JA, Zeldin DC, **Lee CR**. *Endothelial CYP2J2 and CYP2C8 overexpression attenuates lipopolysaccharide-induced adhesion molecule expression in mice*. 10th Annual Winter Eicosanoid Conference. Baltimore, MD, March 11, 2008. "Travel Award" recipient.
94. Theken KN, Deng Y, Kannon MA, DeGraff L, Graves J, Zeldin DC, **Lee CR**. *In vivo effects of acute inflammation on cardiovascular cytochrome P450 and EPHX2 expression in mice*. 10th Annual Winter Eicosanoid Conference. Baltimore, MD, March 11, 2008.
95. **Lee CR**, North KE, Bray MS, Couper DJ, Heiss G, Zeldin DC. *The G-765C promoter polymorphism in cyclooxygenase-2 (PTGS2), aspirin utilization and cardiovascular disease risk: The Atherosclerosis Risk in Communities (ARIC) study*. 9th Annual Winter Eicosanoid Conference. Baltimore, MD, March 13, 2007.
96. **Lee CR**, Bottone FG, Bray MS, North KE, Cook ME, Petrovich RM, Heiss G, Eling TE, Zeldin DC. *Genetic polymorphisms in cyclooxygenase-1 (PTGS1): functional characterization and association with cardiovascular disease risk*. 8th Annual Winter Eicosanoid Conference. Baltimore, MD, March 13, 2006. "Travel Award" recipient.

INVITED PRESENTATIONS

1. *Observational Design Studies: Considerations for Pharmacogenomics and Biomarker Research*. Innovations and Transformations in Pharmaceutical Sciences-Virtual 2020 Conference. Chapel Hill, NC, July 26, 2021.
2. *Lessons Learned from a Mid-Career Translational Scientist: A Long(er) and Wind(ier) Road than Expected*. Graduate Program End-of-Year Symposium, Department of Experimental and Clinical Pharmacology, University of Minnesota College of Pharmacy, Minneapolis, MN (virtual), May 10, 2021.
3. *Observational Design Studies: Considerations for Pharmacogenomics and Biomarker Research*. Innovations and Transformations in Pharmaceutical Sciences-Virtual 2020 Conference. Chapel Hill, NC, July 22, 2020.

4. *CYP2C19-Genotype Guided Antiplatelet Therapy after PCI: Clinical Implications of Emerging Evidence*. Scientific Seminar Series, Marshfield Clinic Research Institute, Marshfield, WI (virtual), May 27, 2020.
5. *Update on CYP2C19-Genotype Guided Antiplatelet Therapy after PCI: Clinical Implications of Emerging Evidence*. Cardiovascular Grand Rounds, UNC Center for Heart and Vascular Care, UNC School of Medicine, Chapel Hill, NC, October 14, 2019.
6. *Clinical Outcomes of CYP2C19 Genotype-Guided Escalation and De-escalation of Antiplatelet Therapy after PCI*. Department of Pharmacy Practice and Translational Research Seminar, University of Houston College of Pharmacy. Houston, TX. April 18, 2019.
7. *Research and Scholarship in Pharmacy (RASP) Pathway*. Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy. Houston, TX. April 18, 2019.
8. *Clinical Outcomes of CYP2C19 Genotype-Guided Escalation and De-escalation of Antiplatelet Therapy after PCI*. Department of Pharmacotherapy and Translational Research Seminar, University of Florida College of Pharmacy. Gainesville, FL. December 7, 2018.
9. *Clinical Outcomes and Sustainability of Using CYP2C19 Genotype-Guided Antiplatelet Therapy*. Graduate Program Seminar Series, Department of Pharmaceutical Sciences, University of Colorado-Denver Skaggs School of Pharmacy. Denver, CO. April 26, 2018.
10. *Genetic Variation in the CYP Epoxygenase Pathway, Endothelial Function, and Cardiovascular Disease Risk*. Genetics and Eicosanoids Symposium, 17th Annual Winter Eicosanoid Conference. Baltimore, MD, March 13, 2018.
11. *Genetic Testing to Predict Medication Effects and Chronic Disease Risk in Cardiology: Is it Ready for Prime Time?* UF Precision Medicine Conference. University of Florida, Orlando, FL, March 9, 2018.
12. *Implementing Pharmacogenetic Testing into Clinical Decision Making: Why, When and How?* Student National Pharmaceutical Association (SNPhA) Regional Conference. Chapel Hill, NC, February 24, 2018.
13. *Clinical Outcomes and Sustainability of Using CYP2C19 Genotype-Guided Antiplatelet Therapy after PCI*. Cardiovascular Grand Rounds, UNC Center for Heart and Vascular Care, Chapel Hill, NC, UNC School of Medicine, November 6, 2017.
14. *How to Interpret Patient Genotyping Data: Case Studies and Panel Discussion*. 11th Annual Chapel Hill Pharmaceutical Sciences Conference. Pharmacy in the Era of Precision Medicine: From Discovery to Implementation. Chapel Hill, NC, May 18, 2017.
15. *Genomics in Medicine: CYP2C19 Genotype-Guided Selection of Antiplatelet Therapy in CAD Patients Undergoing PCI*. Genomics in Medicine Colloquium, Department of Genetics, UNC School of Medicine, Chapel Hill, NC, May 10, 2017.
16. *Application of Personalized Medicine Testing in Cardiology*. Personalized Medicine Conference for Pharmacists. Mission Health, Mountain Area Health Education Center, Asheville, NC, March 4, 2017.
17. *Personalized Medicine Testing in Cardiology*. American Heart Association / American Stroke Association Mid-Atlantic Region Volunteer Leadership Summit, Chapel Hill, NC, February 2, 2017.
18. *Cytochrome P450 Derived Epoxyeicosanoids as a Therapeutic Target in Non-Alcoholic Fatty Liver Disease*. Cytochrome P450 Derived Endogenous Bioactive Lipids Symposium, 21st International Symposium on Microsomes and Drug Oxidations (MDO2016). Davis, CA, October 3, 2016.

19. *The Utility and Feasibility of Using CYP2C19 Genotype to Guide Dual Anti-Platelet Therapy Following PCI: Looking Back and Moving Forward*. Cardiovascular Grand Rounds. UNC Center for Heart and Vascular Care, Chapel Hill, NC, April 14, 2014.
20. *Characterization of the Functional Relationship between Cytochrome P450-Mediated Eicosanoid Metabolism, Inflammation and Cardiometabolic Disease: A Translational Approach*. Bioactive Lipids Symposium, 2013 Drug Discovery and Therapy World Congress, Boston, MA, June 5, 2013.
21. *Immersion in Scientific Inquiry and Scholarship*. Inaugural Educational Renaissance Symposium: Toward a Curricular Transformation, UNC Eshelman School of Pharmacy, Chapel Hill, NC, December 18, 2012.
22. *Translational Characterization of Cytochrome P450-Mediated Eicosanoid Metabolism in Cardiometabolic Disease*. Lipid Oxidation and Chronic Disease Symposium, 2012 Southeast Lipid Research Conference, Pine Mountain, GA, September 28, 2012.
23. *Cytochrome P450 Derived Eicosanoids and Cardiovascular Disease: Translation into Humans*. Department of Pharmacology, New York Medical College, Valhalla, NY, June 13, 2012.
24. *Cytochrome P450 Derived Eicosanoids and Cardiometabolic Disease: Translation into Humans*. Department of Pharmaceutical Science, University of Alberta, Edmonton, Canada, April 27, 2012.
25. *The Role of Cytochrome P450-Derived Epoxyeicosatrienoic Acids (EETs) in Shock*. Eicosanoids and Shock Symposium, 14th Annual Winter Eicosanoid Conference. Baltimore, MD, March 13, 2012.
26. *Clopidogrel-CYP2C19 Black Box Warning: The Elephant in the Room*. ACCP Cardiology Practice and Research Network / AHA Clinical Pharmacology Committee Joint Symposium (*The "Me" Generation of Healthcare: Personalized Medicine in Cardiovascular Disease*), American College of Clinical Pharmacy Annual Meeting, Pittsburgh, PA, October 16, 2011.
27. *Update on Personalized Medicine in Cardiovascular Disease* (break-out session). Heart Failure Management 2011: Established Therapy and New Frontiers, Amelia Island, FL, July 22, 2011.
28. *Epoxyeicosanoids as a Potential Therapeutic for Inflammation and Atherosclerosis*. Therapeutic Targeting of Epoxyeicosanoids Symposium, Experimental Biology 2011, Washington, DC, April 12, 2011.
29. *Cytochrome P450 Epoxygenase Pathway and Cardiovascular Disease: Translation into Humans*. Cardiovascular Disease Epidemiology Program Seminar, Department of Epidemiology, UNC School of Public Health, Chapel Hill, NC, March 29, 2011.
30. *Cytochrome P450 Epoxygenase Pathway and Cardiovascular Disease: Translation into Humans*. Grand Rounds in Clinical Pharmacology. Vanderbilt University Medical Center, Nashville, TN, November 30, 2010.
31. *Personalized Medicine in CVD: Clinical Applications for Pharmacogenomics and Biomarkers* (break-out session). Heart Failure Management 2010: Established Therapy and New Frontiers, Amelia Island, FL, July 16, 2010.
32. *Pro-Con Debate on Prospective Study Designs: Convenience Cohorts versus Randomized Samples*. Conducting Pharmacogenomics Research: A Primer Symposium, 2010 American College of Clinical Pharmacy Spring Practice and Research Forum, Charlotte, NC, April 24, 2010.
33. *Genetic Variation in Soluble Epoxide Hydrolase (EPHX2) is Associated with Vascular Responsiveness to Bradykinin in Humans*. 12th Annual Winter Eicosanoid Conference. Baltimore, MD, March 8, 2010.

34. *Cardiovascular Pharmacogenomics: A Review of Recent FDA Labeling Changes and Future Directions*. 21st Annual Rex Healthcare Update in Cardiology, Cary, NC, February 20, 2010.
35. *Personalized Medicine in CVD: Clinical Applications for Pharmacogenomics and Biomarkers* (break-out session). Heart Failure Management 2009: Established Therapy and New Frontiers, Amelia Island, FL, July 18, 2009.
36. *Biomarkers and Proteomics in Heart Failure* (break-out session). Heart Failure Management 2007: Established Therapy and New Frontiers, Amelia Island, FL, July 14, 2007.
37. *The G-765C Promoter Polymorphism in Cyclooxygenase-2 (PTGS2), Aspirin Utilization and Cardiovascular Disease Risk: The Atherosclerosis Risk in Communities (ARIC) Study*. 9th Annual Winter Eicosanoid Conference. Baltimore, MD, March 13, 2007.
38. *The G-765C Promoter Polymorphism in COX-2 (PTGS2), Aspirin Utilization and Cardiovascular Disease Risk: Atherosclerosis Risk in Communities (ARIC) Study*. Laboratory of Respiratory Biology Seminar, NIH/NIEHS, Research Triangle Park, NC, March 7, 2007.
39. *Cyclooxygenase Polymorphisms: Functional Characterization and Implications for Cardiovascular Disease Risk*. Laboratory of Molecular Carcinogenesis Seminar, NIH/NIEHS, Research Triangle Park, NC, January 16, 2007.
40. *P450 Epoxygenases and Cardiovascular Disease: From Mouse to Man*. Drug Metabolizing Enzymes and Disease Pathogenesis Symposium, 2006 American Association of Pharmaceutical Scientists Annual Meeting, San Antonio, TX, November 1, 2006.
41. *Genetic Variation in the P450 Epoxygenase Pathway and Cardiovascular Disease Risk*. Cardiovascular Disease Epidemiology Program Seminar, Department of Epidemiology, UNC School of Public Health, Chapel Hill, NC, September 12, 2006.
42. *Biomarkers and Genomics in Heart Failure* (break-out session). Heart Failure Management 2006: Established Therapy and New Frontiers, Amelia Island, FL, July 22, 2006.
43. *Cytochrome P450 Derived Eicosanoids, Endothelial Function, and Cardiovascular Disease*. Doctoral Dissertation Defense, Division of Pharmacotherapy and Experimental Therapeutics, UNC School of Pharmacy, Chapel Hill, NC, July 11, 2006.
44. *Genetic Variation in COX-1 and COX-2 and Cardiovascular Disease Risk: The Atherosclerosis Risk in Communities (ARIC) Study*. Office of Clinical Research Seminar, NIH/NIEHS, Research Triangle Park, NC, April 4, 2006.
45. *Genetic Polymorphisms in Cyclooxygenase-1 (PTGS1): Functional Characterization and Association with Cardiovascular Disease Risk*. 8th Annual Winter Eicosanoid Conference. Baltimore, MD, March 13, 2006.
46. *Identification, Functional Characterization, and Potential Cardiovascular Disease Relevance of Polymorphisms in Human COX-1 (PTGS1)*. Division of Pharmacotherapy and Experimental Therapeutics Seminar, UNC School of Pharmacy, Chapel Hill, NC, February 21, 2006.
47. *Identification and Functional Characterization of Polymorphisms in Human Cyclooxygenase-1 (PTGS1)*. Laboratory of Respiratory Biology Seminar, NIH/NIEHS, Research Triangle Park, NC, February 8, 2006.
48. *Genetic Variation in Soluble Epoxide Hydrolase (EPHX2) and Risk of Coronary Heart Disease: an Atherosclerosis Risk in Communities (ARIC) Study*. American Heart Association Scientific Sessions 2005, Dallas, TX, November 15, 2005. Winner, Elizabeth Barrett-Connor Research Award in Epidemiology for Young Investigators.
49. *New Pharmacological Treatment Strategies for Patients with Cardiovascular Disease*. Cardiovascular Update: Disease Management & Prevention, Continuing Education, UNC School of Nursing, Chapel Hill, NC, September 22, 2005.

50. *Biomarkers in Heart Failure* (break-out session). Heart Failure Management 2005: Established Therapy and New Frontiers, Amelia Island, FL, July 16, 2005.
51. *Genetic Variation in Soluble Epoxide Hydrolase (EPHX2) and Risk of Coronary Heart Disease: The Atherosclerosis Risk in Communities (ARIC) Study*. Laboratory of Respiratory Biology Seminar, NIH/NIEHS, Research Triangle Park, NC, April 20, 2005.
52. *EPHX2 Gene Polymorphism (K55R) and Cardiovascular Disease Risk: Results from the ARIC Study*. 7th Annual Winter Eicosanoid Conference. Baltimore, MD, March 22, 2005.
53. *Genetic Variation in Soluble Epoxide Hydrolase (EPHX2) and Risk of Coronary Heart Disease: The Atherosclerosis Risk in Communities (ARIC) Study*. Office of Clinical Research Seminar, NIH/NIEHS, Research Triangle Park, NC, March 8, 2005.
54. *Cytochrome P450 Derived Eicosanoids, Endothelial Function, and Cardiovascular Disease*. Division of Pharmacotherapy and Experimental Therapeutics Seminar, UNC School of Pharmacy, Chapel Hill, NC, November 30, 2004.
55. *Twenty-four Hour Tolbutamide Plasma Concentrations as a Phenotypic Measure of CYP2C9 Activity in Humans*. American College of Clinical Pharmacy Annual Meeting, Dallas, TX, October 25, 2004.
56. *Role of Cytochrome P450-Derived Eicosanoids in Endothelial Dysfunction and Cardiovascular Disease: Atherosclerosis Risk in Communities (ARIC) Ancillary Study*. Laboratory of Respiratory Biology Seminar, NIH/NIEHS, Research Triangle Park, NC, April 28, 2004.
57. *Cytochrome P450 Derived Eicosanoids, Endothelial Function, and Cardiovascular Disease*. Division of Drug Delivery and Disposition Seminar, UNC School of Pharmacy, Chapel Hill, NC, March 2, 2004.
58. *Renal Dysfunction Is Common in Patients with Heart Failure and Preserved Systolic Function: Retrospective Analysis of the Digitalis Investigational Group (DIG) Trial*. American Heart Association Scientific Sessions 2003, Orlando, FL, November 10, 2003.
59. *Acute Coronary Syndromes: Treatment and Management*. Cardiac Medication Update, Continuing Education, UNC School of Nursing, Chapel Hill, NC, October 24, 2003.
60. *New Medications on the Horizon*. New Directions in the Management of Heart Failure, Continuing Education, UNC School of Nursing, Chapel Hill, NC, October 23, 2002.
61. *CYP2C9 Genotype:Phenotype Relationships in Humans*. In-Vitro / In-Vivo Correlates of Drug Disposition Seminar, UNC School of Pharmacy, Chapel Hill, NC, February 21, 2002.
62. *Metabolic Consequences of CYP2C9 Genetic Polymorphisms with Losartan*. American College of Clinical Pharmacy Annual Meeting, Cardiology Practice and Research Network, Tampa Bay, FL, October 23, 2001.
63. *Evaluation of Phenotypic Probes of CYP2C9 Activity in a Genotyped Population*. American College of Clinical Pharmacy Annual Meeting, Cardiology Practice and Research Network, Los Angeles, CA, November 6, 2000.

RESEARCH FUNDING – Active

Extramural

1 R01 HL149752-01-05

Cavallari, LH & Lee, CR (MPI)

Title: *Precision Antiplatelet Therapy after Percutaneous Coronary Intervention*
Sponsor: NIH/NHLBI
Dates: 7/15/20 – 6/30/25
Direct Costs: \$2,753,769 (total); \$809,319 (UNC)
Effort: 25%
Role: Multiple Principal Investigator (MPI), Consortium Lead Investigator

1 R01 HD098742-01-04

Lee, CR (PI)

Title: *Mechanisms of Altered Hepatic Drug Metabolism and Transport in Pregnancy*
Sponsor: NIH/NICHHD
Dates: 4/1/20 – 3/31/24
Direct Costs: \$1,060,523
Effort: 27.5%
Role: Principal Investigator

R03 HD092370-01-02

Bogges, KA (PI)

Title: *Phase II Study of Nicotinamide (vitamin B3-amide) in Early-Onset Preeclampsia*
Sponsor: NIH/NICHHD
Dates: 9/1/17 – 8/31/21 (2-years plus no cost extension)
Direct Costs: \$100,000
Effort: 2.5%
Role: Co-Investigator

RESEARCH FUNDING – Completed

Extramural

AHA 18POST33960403 (Post-Doctoral Fellowship)

Khatri, R (PI)

Title: *Predicting Maternal Changes in Antihypertensive Drug Metabolism and Exposure during Pregnancy*
Sponsor: American Heart Association
Dates: 7/1/18 – 6/30/20 (early termination 11/1/2019)
Direct Costs: \$114,368
Effort: 0%
Role: Sponsor

Project ID #18-2862 (Research Services Agreement)

Lee, CR (PI)

Title: *IGNITE Network CYP2C19-Clopidogrel Expansion Project*
Sponsor: University of Florida
Dates: 10/1/18 – 9/30/19
Direct Costs: \$4,770
Effort: 0%
Role: Principal Investigator

AHA 16GRNT29300003 (Grant-in-Aid)

Lee, CR (PI)

Title: *Novel Biomarkers of Eicosanoid Metabolism in Coronary Artery Disease*
Sponsor: American Heart Association, Mid-Atlantic Affiliate
Dates: 7/1/16 – 6/30/19 (2-years plus no cost extension)
Direct Costs: \$140,000
Effort: 15%
Role: Principal Investigator

AFPE Gateway to Research Scholarship

Wells, MA (PI)

Title: *Translational Evaluation of Cytochrome P450-Derived Eicosanoid Metabolites as a Biomarker in Non-Alcoholic Steatohepatitis (NASH) Patients*
Sponsor: American Foundation for Pharmaceutical Education
Dates: 6/30/15 – 6/30/16
Direct Costs: \$5,000
Effort: 0%
Role: Major Advisor

AHA 13PRE16470017 (Pre-Doctoral Fellowship)

Oni-Orisan, A (PI)

Title: *Soluble Epoxide Hydrolase and Cardioprotection: Translation from Mice to Humans*
Sponsor: American Heart Association, Mid-Atlantic Affiliate
Dates: 7/1/13 – 6/30/15
Direct Costs: \$50,000
Effort: 0%
Role: Sponsor

R01 GM088199-01-05

Lee, CR (PI)

Title: *Cytochrome P450 Derived Eicosanoids and Inflammation*
Sponsor: NIH/NIGMS
Dates: 8/1/09 – 5/31/15 (5-years plus no cost extension)
Direct Costs: \$1,053,568
Effort: 40%
Role: Principal Investigator

R01 GM088199-03-05S1

Lee, CR (PI)

Title: *Cytochrome P450 Derived Eicosanoids and Inflammation (Research Supplement to Promote Diversity in Health-Related Research)*
Sponsor: NIH/NIGMS
Dates: 6/1/11 – 5/31/14
Direct Costs: \$47,400
Effort: 0%
Role: Principal Investigator

AFPE Pre-doctoral Fellowship Award

Oni-Orisan, A (PI)

Title: *The Role of Soluble Epoxide Hydrolase in Recovery Following Acute Myocardial Infarction: Translation from Mouse to Human*
Sponsor: American Foundation for Pharmaceutical Education
Dates: 9/1/12 – 8/31/13
Direct Costs: \$6,500
Effort: 0%
Role: Major Advisor

AHA 11PRE7240059 (Pre-Doctoral Fellowship) Schuck, RN (PI)
Title: *Translational Characterization of Arachidonic Acid Metabolism in Vascular Inflammation and Cardiovascular Disease*
Sponsor: American Heart Association, Mid-Atlantic Affiliate
Dates: 7/1/11 – 6/30/13
Direct Costs: \$46,000
Effort: 0%
Role: Sponsor

AFPE Pre-doctoral Fellowship Award Theken, KN (PI)
Title: *Role of Cytochrome P450-Mediated Eicosanoid Metabolism in Atherosclerotic Cardiovascular Disease*
Sponsor: American Foundation for Pharmaceutical Education
Dates: 9/1/08 – 8/31/11
Direct Costs: \$18,000
Effort: 0%
Role: Major Advisor

T32 HL069768 (Ruth L. Kirschstein Institutional NRSA) Maeda, N (PI)
Title: *Pre-Doctoral Training Program in Integrative Vascular Biology*
Sponsor: NIH/NHLBI
Dates: 7/1/10 – 6/30/11
Direct Costs: \$30,000
Effort: 0%
Role: Major Advisor (Robert N. Schuck)

AHA 0765247U (Beginning Grant-in-Aid) Lee, CR (PI)
Title: *P450 Epoxygenase Pathway and Atherosclerotic Cardiovascular Disease*
Sponsor: American Heart Association, Mid-Atlantic Affiliate
Dates: 7/1/07 – 6/30/09
Direct Costs: \$120,000
Effort: 20%
Role: Principal Investigator

F32 ES012856 (Ruth L. Kirschstein Individual NRSA) Lee, CR (PI)
Title: *CYP2J2 Derived Eicosanoids and Endothelial Function*
Sponsor: NIH/NIEHS
Dates: 9/30/03 – 9/29/06
Direct Costs: \$156,930
Effort: 100%
Role: Principal Investigator
Co-Sponsors: J. Herbert Patterson and Darryl C. Zeldin

Intramural

UNC Creativity Hub Pilot Award

Gordon-Larsen, P (PI)

Title: *Heterogeneity in Obesity: Transdisciplinary Approaches for Precision Research and Treatment*
Sponsor: UNC Office of the Vice Chancellor for Research
Dates: 7/1/18 – 6/30/20
Direct Costs: \$500,000
Effort: 0%
Role: Co-Investigator

RX03612214 (Tier 3 Pilot Grant)

Wiltshire, T (PI)

Title: *Pharmacogenetic Implementation: The Actionable Genome*
Sponsor: The UNC Eshelman Institute for Innovation
Dates: 6/1/17 – 12/31/19
Direct Costs: \$435,276
Effort: 0%
Role: Co-Investigator

RX03512212 (Tier 1 Pilot Grant)

Lee, CR (PI)

Title: *Solving the Mystery of Highly Variable Drug Disposition in Pregnant Women: Are Unique Hepatic Drug Metabolizing Enzymes Activated during Pregnancy?*
Sponsor: The UNC Eshelman Institute for Innovation
Dates: 10/1/15 – 3/31/17
Direct Costs: \$49,855
Effort: 15%
Role: Lead Innovator

TraCS # 550KR61307 (TraC\$5K-\$50K Pilot Grant Program)

Bogges, KA (PI)

Title: *A Dose Escalation Study of Nicotinamide Supplementation in Early Onset Preeclampsia*
Sponsor: The North Carolina Translational and Clinical Sciences Institute
Dates: 3/1/14 – 2/28/15
Direct Costs: \$50,000
Effort: 0%
Role: Co-Investigator

UNC Small Grant Program

Lee, CR (PI)

Title: *Functional Characterization of an Interaction between the -765G>C Polymorphism in Cyclooxygenase-2 and Aspirin Use in Humans*
Sponsor: UNC University Research Council
Dates: 5/1/10 – 4/30/12
Direct Costs: \$5,000
Effort: 0%
Role: Principal Investigator

TraCS #10KR40907 (TraC\$10K Pilot Grant Program) Lee, CR (PI)

Title: *Eicosanoid Metabolism, Endothelial Function and Atherosclerotic Cardiovascular Disease*
Sponsor: The North Carolina Translational and Clinical Sciences Institute
Dates: 11/1/09 – 10/31/10
Direct Costs: \$10,000
Effort: 0%
Role: Principal Investigator

TraCS #2KR70909 (TraC\$2K Pilot Grant Program) Schuck, RN (PI)

Title: *Functional Characterization of a 5-Lipoxygenase Polymorphism in Patients with Atherosclerotic Cardiovascular Disease*
Sponsor: The North Carolina Translational and Clinical Sciences Institute
Dates: 9/1/09 – 8/31/10
Direct Costs: \$2,000
Effort: 0%
Role: Major Advisor

UNC Junior Faculty Development Award Lee, CR (PI)

Title: *Dysfunctional Eicosanoid Metabolism and Cardiovascular Disease*
Sponsor: UNC Office of the Provost
Dates: 1/1/08 – 12/31/08
Direct Costs: \$7,500
Effort: 0%
Role: Principal Investigator

UNC Investments in the Future Patterson, WC (PI)

Title: *Understanding Clinical Cardiovascular Disease and Health Disparities in North Carolina Using a Systems Biology Approach*
Sponsor: UNC School of Medicine
Dates: 7/1/07 – 6/30/08
Direct Costs: \$243,333
Effort: 5%
Role: Co-Investigator

UNC Small Grant Program Lee, CR (PI)

Title: *Evaluation of a New Strategy for the Treatment of Vascular Inflammation*
Sponsor: UNC University Research Council
Dates: 5/1/07 – 4/30/09
Direct Costs: \$5,000
Effort: 0%
Role: Principal Investigator

TEACHING RECORD

Professional

Doctor of Pharmacy (Pharm.D.)

Course Director

PHCY 726	Research and Scholarship in Pharmacy III	2018
PHCY 725	Research and Scholarship in Pharmacy II	2017
PHCY 624	Research and Scholarship in Pharmacy I	2017 - 2021

Course Co-Director

PHCY 726	Research and Scholarship in Pharmacy III	2019 - 2021
PHCY 510	Foundations in Clinical Pharmacology	2016
DPET 813	Advanced Cardiovascular Pharmacotherapy	2009 - 2015

Instructor

PHCY 726	Research and Scholarship in Pharmacy III	2018 - present
PHCY 725	Research and Scholarship in Pharmacy II	2017 - present
PHCY 624	Research and Scholarship in Pharmacy I	2017 - present
PHCY 510	Foundations in Clinical Pharmacology	2016 - 2019
PHCY 444	Pharmacotherapy 4: Cardiology / Nephrology	2009 - 2016
PHCY 433	Drug Literature Analysis and Interpretation	2007 - 2009
DPET 813	Advanced Cardiovascular Pharmacotherapy	2000 - 2016

Recitation Facilitator

PHCY 601	Patient Care Lab	2016
PHCY 402	Pharmaceutical Care Lab II	2009 - 2015
PHCY 404	Pharmaceutical Care Lab IV	2008 - 2016
PHCY 403	Pharmaceutical Care Lab III	2007 - 2012
PHCY 405	Pharmaceutical Care Lab V	2007 - 2010
HAICC	Health Affairs Interdisciplinary Case Conference	2007 - 2009

Reserve Facilitator

PHCY 450	Pharmacotherapy 8: Problems	2008 - 2013
----------	-----------------------------	-------------

Graduate

Ph.D. in Pharmaceutical Sciences

Course Director

DPET 833	Experimental Design Considerations in Clinical Research	2016 - present
DPET 822	Advanced Clinical Pharmacy	2009 - 2016

Course Co-Director

DPET 833	Experimental Design Considerations in Clinical Research	2013 - 2015
----------	---	-------------

Faculty Advisor

PHRS	First Year Group, Pharmaceutical Science Graduate Program	2011
------	---	------

Instructor

DPOP 872	Proposal Writing	2018 - present
DPMP 815	Drug Metabolism Module	2018 - present
DPET 837	Precision Therapeutics Through Genomics	2018 - present
DPET 833	Experimental Design Considerations in Clinical Research	2013 - present
DPET 832	Introduction to Applied Pharmacogenomics	2008 - 2016
MOPH 810	Drug Metabolism	2005 - 2015

Small Group Discussion Facilitator

DPET 822	Advanced Clinical Pharmacy	2009 - 2016
----------	----------------------------	-------------

Post-Graduate

UNC Clinical Research / Drug Development Fellowship program

Instructor

DPET	T32 Fellows Forum	2014 - present
DPET	Post-Doctoral 'Fellows Course'	2007 - 2008

MENTORING RECORD

Professional / Undergraduate

Doctor of Pharmacy (Pharm.D.)

Research Advisor, Research and Scholarship in Pharmacy (RASP) pathway

Julian Garcia		2021 - present
Valeria Laboy Collazo		2021 - present
Marshall Winget		2020 - present
Lindsay Ratner		2019 - present
Rachel Black		2017 - 2020
Spenser Smith		2017 - 2020
Jesse Martin	(ASCPT Presidential Trainee)	2016 - 2020
Melody Robbins		2016 - 2019

Research Advisor, Honors Program

Alexandra Cervantes		2015 - 2018
Nan Wang		2015 - 2017
Amy Li		2015 - 2017
Michael Wells	(AFPE Gateway to Research Scholar)	2014 - 2016

Research Advisor, PY4 students

Kasey Hamrick		2015 - 2016
Erin Christensen		2014 - 2015
Ryan Danford		2014 - 2015
Chris Abernethy (co-advisor: Dr. Jo Ellen Rodgers)		2009 - 2010

Doctor of Medicine (M.D.)

Research Advisor, Carolina Medical Student Research Program (T35-DK007386)

Brian Wood (co-advisor: Dr. George A. Stouffer)		2020 - 2021
Chelsea Gustafson (co-advisor: Dr. George A. Stouffer)		2019 - 2020
Melissa Klein (co-advisor: Dr. George A. Stouffer)		2017 - 2018
Nicholas Varunok (co-advisor: Dr. George A. Stouffer)		2015 - 2016

Undergraduate (B.S.)

Research Advisor

Bobbie Nguyen (major: chemistry)		2013 - 2016
----------------------------------	--	-------------

Graduate

Ph.D. in Pharmaceutical Sciences

Major Advisor

Akinyemi Oni-Orisan, Pharm.D.	(AFPE & AHA Predoctoral Fellow)	2010 - 2015
Robert N. Schuck, Pharm.D.	(AHA Predoctoral Fellow)	2008 - 2013
Katherine N. Theken, Pharm.D.	(AFPE Predoctoral Fellow)	2006 - 2011

Dissertation Committee

William Murphy, Pharm.D. (Chair)	(Certara Simcyp Division Grant)	2021 - present
Jiawei Zhou, B.S. (Chair)		2020 - present
Jacqueline Gerhart, M.S. (Chair)	(AFPE Predoctoral Fellow)	2019 - present

James Beaudoin, M.S.	(NIH NSRA F31 Predoctoral Fellow)	2017 - 2020
Olivia Dong, M.P.H. (Chair)	(AHA Predoctoral Fellow)	2016 - 2019
Lawrence Ku, M.D. (Chair)		2015 - 2019
Christina Won, Pharm.D.		2012
Jasmine (Talameh) Luzum, Pharm.D.	(AFPE Predoctoral Fellow)	2009 - 2012
Huali Wu, M.S.		2009 - 2010
<i>Ph.D. in Epidemiology</i>		
<u>Dissertation Committee</u>		
Amanda Seyerle, M.S.		2015 - 2016
<i>External to UNC-Chapel Hill</i>		
<i>Ph.D. in Pharmaceutical Sciences (University of Alberta)</i>		
<u>Doctoral Final Oral Examination Committee (external member)</u>		
Ketul R. Chaudhary		2012
<i>M.S. in Clinical Research (Duke University)</i>		
<u>Research Advisor</u>		
Ewa Marczak, Ph.D.		2009 - 2011
<i>Ph.D. in Nursing (UNC-Greensboro)</i>		
<u>Dissertation Committee</u>		
Janis Puglisi, MSN, APRN, FNP-BC		2013
<u>Post-Graduate</u>		
<i>Post-Doctoral Research Associates</i>		
<u>Major Advisor</u>		
Muluneh Fashe, M.S., Ph.D.		2020 - present
Raju Khatri, M.S., Ph.D., DABT	(AHA Postdoctoral Fellow)	2017 - 2019
Weibin Zha, B.S. Pharm., Ph.D.		2012 - 2013
Yangmei Deng, M.D., Ph.D.		2007 - 2011
<i>UNC Clinical Research / Drug Development Fellowship program</i>		
<u>Major Advisor</u>		
Anh Nguyen, Pharm.D.		2021 - present
Ian Mulrenin, Pharm.D.		2020 - 2021
Megan Gower, Pharm.D.		2019 - 2020
Alexis Williams, Pharm.D.		2018 - 2019
Hitesh Patel, Pharm.D. (co-advisor: Dr. Robert Dupuis)		2017 - 2018
Melissa Polasek, Pharm.D.		2014 - 2015
John Andrew Lee, Pharm.D.		2013 - 2014
Robert Wittorf, Pharm.D.		2012 - 2013
Brian Simmons, Pharm.D., M.S.C.R. (co-advisor: Dr. J. Herbert Patterson)		2011 - 2012
Savanna Steele, Pharm.D.		2010 - 2011
Bryant Tran, Pharm.D., M.S. (co-advisor: Dr. Jo Ellen Rodgers)		2009 - 2010
Kyle Ellis, Pharm.D.		2008 - 2009
Almasa Bass, Pharm.D. (co-advisor: Dr. J. Herbert Patterson)		2007 - 2008
<i>Visiting Scholar</i>		
<u>Research Advisor</u>		
Vindhya B. Sriramoju, M.D. (co-advisor: Dr. George A. Stouffer)		2015 - 2017

Pharmacy Residency

Faculty Mentor, Residency Teaching Certificate Program

Erin Mays, Pharm.D.	2020 - 2021
Frank Tillman, Pharm.D.	2019 - 2020
Molly Howard, Pharm.D.	2013 - 2014
Brian Murray, Pharm.D.	2010 - 2011

Staff

Research Technician

Supervisor

Taryn Miner, M.S.	2020 - present
Natasha Kulick, B.A.	2018 - 2019
Rebecca Rementer, M.S.	2016 - 2018
Kimberly Vendrov, B.S.	2011 - 2015
M. Alison Kannon, B.S.	2006 - 2011

Social/Clinical Research Assistant

Supervisor

Grace Tillotson, B.S.	2021 - present
Natasha Kulick, B.A.	2020 - 2021

PROFESSIONAL SERVICE

UNC-Chapel Hill

UNC Eshelman School of Pharmacy

Standing Committees

Full Professors Committee	2021 - present
Budget Committee	2020
Partnership in Patient Care 2.0 Research Working Committee	2018 - 2020
Research and Scholarship in Pharmacy (RASP) Oversight Committee	2016 - present
RASP Oversight Committee Chair	2016 - 2021
Curricular Transformation Steering Committee	2012 - 2016
Research/Scholarship Track Planning Team (Chair)	2016
Electives Planning Team	2016
Pharmacy Innovation and Problem Solving Planning Team	2016
Pharmacy Innovation and Problem Solving Committee (Chair)	2013
Scholarship Subcommittee (Chair)	2012
Assessment Committee	2010 - 2012
Student Portfolio Subcommittee (Chair)	2010 - 2011
Graduate Education Committee	2008 - 2017
Admissions Committee	2008 - 2010
Pharm.D./Ph.D Program Committee	2007 - 2008

Ad Hoc Committees

Strategic Planning Advisory Committee	2020
COVID-19 Crisis Management, Research Enterprise Subcommittee	2020
COVID-19 Clinical Research Review Committee	2020
ACPE Accreditation Self-Assessment, Educational Program for the Doctor of Pharmacy Degree subcommittee (Reviewer)	2018 - 2019
Virtual Patient Planning Team	2016 - 2017
Pharm.D./Ph.D Program Committee	2012
ACPE Accreditation Self-Assessment, Faculty/Staff subcommittee	2010 - 2011

Search Committees

Division Chair, Division of Pharmacotherapy and Experimental Therapeutics	2019 - 2020
Fixed-Term Assistant/Associate Professor (Biostatistics), Division of Pharmacotherapy and Experimental Therapeutics (Chair)	2019 - 2020
Program Manager (RASP / YIP), Office of Student and Curricular Affairs	2019 - 2020
Dean, UNC Eshelman School of Pharmacy	2019
Assistant Director of Student Affairs, Office of Student Affairs	2012

Miscellaneous

Academic Advisor, Pharm.D. students	2014 - 2017
Interviewer, Doctor of Pharmacy program applicants	2007 - 2019
Volunteer Pharmacist, IFC Shelter	2007 - 2008

Division of Pharmacotherapy and Experimental Therapeutics (DPET)

Administrative

Vice Chair for Research and Graduate Education	2019 - present
Division Director of Graduate Studies	2016 - 2017
Division Director of Graduate Admissions	2008 - 2016

Ad Hoc Committees

DPET Ph.D. Clinical-Track Stipend Supplement committee	2012
Written Qualifying Exam committee	2008 - 2010
Graduate Student Clinical Experience committee	2007

Miscellaneous

Interviewer, DPET Ph.D. program applicants (Recruitment Weekend)	2007 - present
Interviewer, DPET fellowship program applicants	2007 - present

North Carolina Translational and Clinical Sciences Institute (NC TraCS)

Internal Grant Review Committee

Study Section Member, K-Scholars Program	2019 - present
--	----------------

UNC McAllister Heart Institute (MHI)

Ad Hoc Committee

Co-Organizer, 2 nd Annual MHI Faculty Retreat	2019
--	------

UNC Health Care and UNC School of Medicine

Ad Hoc Committee

Program for Precision Medicine and Health (PPMH) Steering Committee	2020 - present
PPMH / Information Services Division	
Genetics and Genomics Governance Committee	2019 - present
Epic Genomics Integrated Workgroup	2019 - 2020

UNC Office of Research Development

Internal Grant Review Committee

American Diabetes Association Pathway to Stop Diabetes Award	2013 - 2014
--	-------------

National Institutes of Health

Study Section (ad hoc)

Special Emphasis Panel, 2021/05 ZRG1 EMNR-D (56)	2021
Special Emphasis Panel, 2020/10 ZRG1 EMNR-S (55)	2020
Special Emphasis Panel, 2017/03 ZRG1 GGG D (90)	2017
Special Emphasis Panel, 2013/08 ZRG1 BDCN-A (40)	2013
Special Emphasis Panel, 2010/05 ZES1 LWJ-V (01) 2	2010

Research Network

Implementing GeNomics In PracTice (IGNITE) Network, NIH/NHGRI
Affiliate Member (UNC Lead Investigator) 2015 - present
Pharmacogenomics Working Group 2015 - 2021

Institutional Review Board

Reviewer (ad hoc), NIH/NIEHS 2014 - 2017
Scientific Member (standing), NIH/NIEHS 2009 - 2014

Scientific Reviewer (ad hoc)

Office of Clinical Research, NIH/NIEHS 2011 - 2013

Professional Organizations

American College of Clinical Pharmacy (ACCP)

Fellow 2011 - present
Full Member 2003 - present
Associate Member in Training 2000 - 2003
Cardiology Practice and Research Network (PRN) 2000 - present

Service

Research Affairs Committee 2021 - present
Cardiology PRN Research and Scholarship Committee 2020 - present
Reviewer, Research Institute Futures Grant, Junior Investigator 2019
Reviewer, Clinical Research Challenge 2019
Member, Cardiology PRN Nominations Committee 2017 - 2019
Reviewer, Ambulatory Care Self-Assessment Program 2017
Reviewer, Resident and Fellow Travel Awards 2010 - 2011
Cardiology PRN Resident and Student Travel Award Committee 2008 - 2013
Abstract Reviewer, Annual & Spring Meetings 2003 - present

American Society of Clinical Pharmacology and Therapeutics (ASCPT)

Full Member 2007 - present
Associate Member 2002 - 2007

Service

Scientific Program Committee 2019 - present
Abstract Reviewer, Annual Meeting 2016 - present

Clinical Pharmacogenomics Implementation Consortium (CPIC)

Scientific Member 2017 - present

Service

Guideline Writing Committee, *CYP2D6*-Beta-blockers 2021 - present
Subcommittee, *CYP2C19* Allele Function Assignment 2021
Guideline Writing Committee, *CYP2C19*-Clopidogrel (lead author) 2019 - present
Subcommittee, *CYP2C9* Allele Function Assignment 2019
Guideline Writing Committee, *CYP2C9*-NSAIDs 2018 - 2019

American Heart Association (AHA)

Fellow 2015 - present
Professional Member 2003 - present
Council on Clinical Cardiology 2014 - present
Council on Genomic and Precision Medicine (GPM) 2009 - present
Council on Epidemiology and Prevention 2005 - 2009
Council on Arteriosclerosis, Thrombosis and Vascular Biology 2003 - 2014

<u>Service</u>		
Membership & Communications Committee, Council on GPM		2014 - 2018
Clinical Pharmacology Committee, Council on Clinical Cardiology		2013 - 2017
<i>American College of Cardiology (ACC)</i>		
Member, Cardiovascular Team		2019 - present
<u>Service</u>		
Abstract Reviewer, Scientific Sessions		2020 - present
<i>American Society for Pharmacology and Experimental Therapeutics (ASPET)</i>		
Member		2006 - present
<u>Service</u>		
Co-Chair, <i>Therapeutic Targeting of Epoxyeicosanoids</i> symposium		2011
Divisions of Cardiovascular/Molecular Pharmacology, Experimental Biology		
<i>The Eicosanoid Research Association</i>		
<u>International Winter Eicosanoid Conference</u>		
Co-Chair, <i>Drug Development</i> session		2020
Co-Organizer/Chair, <i>Genetics and Eicosanoids</i> session		2018
Scientific Advisor		2015 - present
Poster Session Co-Chair, International Winter Eicosanoid Conference		2012 - 2016
Organizer/Chair, <i>Advances in Eicosanoid Biology in Humans</i> session		2011
Poster Session Judge		2007 - 2016
<i>International Society for the Study of Xenobiotics (ISSX)</i>		
Co-Chair, <i>CYP450 Derived Endogenous Bioactive Lipids</i> symposium		2016
21 st International Symposium on Microsomes and Drug Oxidations		
<u>Editorial Board</u>		
Frontiers in Genetics (Pharmacogenetics and Pharmacogenomics)		2012 - present
Prostaglandins and Other Lipid Mediators		2011 - present
Frontiers in Physiology (Vascular Physiology)		2010 - present
Current Clinical Pharmacology		2005 - 2013
<u>Guest Editor</u>		
Guest Editor, Prostaglandins and Other Lipid Mediators		
<i>Special Issue: Translational Significance of EETs and Other Fatty Acids in Obesity and Diabetes</i> . Volume 125, Pages 1-118 (September 2016)		2016
Research Topic Host, Frontiers in Pharmacology		
<i>Double Edge Sword: Epoxyeicosatrienoic Acids in Health and Disease</i>		2014
<u>Manuscript Referee</u>		2006 - present
Am J Pathol	Cardiovasc Res	
Am J Physiol Heart Circ Physiol	Circulation	
Am J Physiol Endocrinol Metab	Circ Cardiovasc Interv	
Am J Physiol Regul Integr Comp Physiol	Circ Genom Precis Med	
Ann Pharmacother	Circ Heart Fail	
Antioxid Redox Signal	Clin Pharmacol Ther	
Arterioscler Thromb Vasc Biol	Clin Transl Sci	
Atherosclerosis	Crit Care Med	
BMC Med Genet	Drug Metab Dispos	
Br J Clin Pharmacol	Environ Health Perspect	
Cancer Res	Expert Opin Drug Discov	

Front Pharmacol
Front Physiol
Gastroenterology
Genet Med
Hypertension
JAMA
J Am Coll Cardiol
J Am Heart Assoc
J Am Soc Nephrol
J Invasive Cardiol
J Transl Med
J Pharmacol Exp Ther
Obesity

Personalized Medicine
Pharmacogenet Genomics
Pharmacogenomics
Pharmacogenomics J
Pharmacol Res
Pharmacol Ther
Pharmacotherapy
Physiol Rev
Proc Natl Acad Sci U S A
Prostaglandins Other Lipid Mediat
Sci Rep
Stroke